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CHAPTER 1 - INTRODUCTION  
1.1 Gene expression by Histone Deacetylase (HDAC) proteins 
The nucleosome is a unit of DNA packaged around a histone protein core 
(Figure 1.1).1 The four core histone proteins (histone octomers, pink) are 
wrapped by the DNA double helix (gray), which form chromosomes (violet) 
through highly condensed nucleosomes. The nucleosomes carry epigenetically 
inherited information in the covalent modifications of the core histones. Covalent 
modifications of lysine residues located on histone N-terminal tails alter gene  
expression.  
 
Figure 1.1 Epigenetic mechanisms.
1
 Histone octomers (pink), DNA double stand (gray), and 
chromosomes (violet). Reused with permission 
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Among the covalent modifications, the acetylation status of histone lysines 
is governed by histone deacetylase (HDAC) proteins and histone 
acetyltransferase (HAT) proteins and is in equilibrium (Figure 1.2). HDAC and 
HAT proteins are two key enzymes that regulate gene transcription. The neutral, 
acetylated lysine allows DNA to interact with transcription factors to promote 
gene expression. Deacetylated positively charged lysine residues interact with 
the negatively charged phosphate backbone of DNA. The tight electrostatic 
interaction between the additional lysine residues and the negatively charged 
DNA backbone prevents activation with gene transcription. The overexpression 
of HDAC proteins shifts the equilibrium to the unmodified state and results in 
aberrant transcription in some cancer cells.2 More specifically, overexpression of 
HDAC proteins induces repression of transcription and alteration in the 
accessibility of genes to transcriptional proteins causes reduced gene 
expression. Since decreasing gene expression can cause a variety of diseases, 
including cancers, the family of HDAC proteins has been studied. 
 
Figure 1.2 The equilibrium activities of histone acetyltransferase (HAT) and deacetylase (HDAC)  
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1.2 HDAC protein family 
The HDAC protein family consists of 18 members and is divided into four 
classes based on size, cellular localization, number of catalytic active site, and 
homology to yeast HDAC protein (Table 1.1).3 Class I includes HDAC1, HDAC2, 
HDAC3, and HDAC8. Class II includes HDAC4, HDAC5, HDAC6, HDAC7, 
HDAC9, and HDAC10. Class IV includes HDAC11 as the sole member because 
it displays similarities to both class I and II. Class III are NAD+-dependent 
proteins, referred to as sirtuins (SIRT 1-7).4 Class I, II, and IV are metal ion-
dependant proteins and are sensitive to the inhibitors in this dissertation.  
Table 1.1. HDAC family 
Metal ion-dependent NAD
+
-dependent 
Class I Class II Class IV Class III 
HDAC1 
HDAC2 
HDAC3 
HDAC8 
HDAC4 
HDAC5 
HDAC6 
HDAC7 
HDAC9 
HDAC10 
HDAC11 SIRT (1-7) 
 
Class I HDAC proteins (HDACs) are found in cancers, including ovarian 
(HDAC1, 2, and 3),5 gastric (HDAC2),6 and lung cancers (HDAC1 and HDAC3).7 
Class I HDACs are produced at higher levels in ovarian cancers compared to 
normal ovarian tissues, as assessed using small interfering RNA methodology.5 
Strong expression of HDAC2 was found in 44 out of a total of 71 gastric tumors.6 
HDAC3 is elevated in 92% of squamous cell lung carcinomas, as assessed using 
4 
immunoblot analysis.7 HDAC8 is involved in acute myeloid leukemia (AML).8  A 
common form of AML results from an abnormal fusion protein, Inv1, that binds 
HDAC 8. Overexpression of class II HDAC6 is observed in breast and ovarian 
cancer tissues.9 Cell motility was increased by transfecting at HDAC6 expression 
plasmid into the breast cancer MCF-7 cells. Class II HDAC 10 protein is involved 
in the formation of tumors of skeletal muscle.10 HDAC10 was detected at the 
highest level in the skeletal muscle tumor SJRH30 rhabdomyosarcoma cell line. 
The different activities that connect each HDAC isoform with cancer formation 
have been given significant attention on the pharmaceutical and carcinoma 
studies.5, 9   
Even though each individual HDAC protein is involved in the formation of 
cancers, the role of each isoform in carcinogenesis is not clear yet. Therefore, 
elucidating the molecular mechanism connecting the HDAC activity of each 
isoform to cancer formation would facilitate studies that lead to treatment of 
diseases. To comprehensively understand the role of individual HDAC proteins in 
the growth and progression of cancer, development of selective HDAC inhibitors 
is required. 
1.3 HDAC inhibitors 
New approaches towards studying the causes and treatments of cancer 
have been rigorously studied since cancers are one of major causes of death in 
the United States. With a role in cancer, several HDAC inhibitor drugs are in 
clinical trials for treatment of cancer.11 Specifically, suberoyl anilide hydroxamic 
acid (SAHA, Vorinostat) was the first HDAC inhibitor approved by the Food and 
5 
Drug Administration (FDA) for treatment of cutaneous T-cell lymphoma (CTCL).12 
Another recent FDA-approved HDAC inhibitor is depsipeptide (romidepsin, 
FK228), also for treatment for CTCL.13 Currently, most HDAC inhibitors are pan-
inhibitors, which similarly inhibit all HDAC proteins. Therefore, developing 
selective inhibitors would aid studies connecting HDAC activity to cancer 
formation. 
Most metal ion-dependent HDAC inhibitors, including SAHA, have a 
similar structure construction consisting of a capping group that is solvent-
exposed, a carbon linker that is surrounded by a hydrophobic tunnel, and a metal 
binding moiety that is buried in the protein active site (Figure 1.3).  
 
Figure 1.3. Structures of metal ion-dependent HDAC inhibitors 
The crystal structure of SAHA bound in the active site of a bacterial 
homologue support that the SAHA anilide capping group is solvent-exposed near 
amino acids at the entrance of the active site, the linker positions in the 
hydrophobic channel, and the hydroxamic acid is located near the zinc atom at 
bottom of the active site (Figure 1.4). However, slight differences in the active 
sites of the human HDAC isoforms are not known in detail because limited 
crystallographic analysis is only available for HDAC2,14 HDAC3,15 HDAC4,16 
6 
HDAC7 and HDAC8.17 Therefore, design of isoform-selective HDAC inhibitors 
that inhibit only related HDAC proteins is challenging. 
 
Figure 1.4. Structure of SAHA bound to an HDAC-like protein.
18
 Reused with permission. 
1.4 Inhibitor selectivity 
Currently, most HDAC inhibitors, including SAHA, nonspecifically inhibit all 
eleven metal ion-dependent HDAC proteins. As a promising hypothesis, the non-
selective HDAC inhibitors might cause cancer patients in the clinic to suffer from 
the side effects, such as fatigue, anorexia, diarrhea, and cardiac arrhythmia.19 
The clinical toxicity of selective inhibitors is unknown because there is no HDAC 
isoform selective inhibitor at present. In addition, the similarity in the active sites 
of the isoforms has challenged inhibitor design.20 Elucidating the relationship 
between inhibitor selectivity and clinical toxicity might not only help understand 
7 
the role of the HDAC isoform function, but also contribute to the development of 
chemotherapies with fewer side effects for cancer patients. 
1.5 Rationale for the synthesis of SAHA analogues containing 
substituents on the carbon linker 
Towards creating isoform selective inhibitors, the structural regions of 
HDAC inhibitors have been studied. Particularly, the capping region and metal 
binding moiety have been extensively modified.21 The influence of substituents 
on the linker region is relatively less studied, although the hydrocarbon linker has 
been investigated, such as varying chain length, producing points of unsaturated 
chain, and adding an aryl or cyclohexyl ring.22 However, MS-275, which displays 
selectivity for class I23, contains an aryl ring in the linker region (Figure 1.3). The 
intra-chain aryl group structure of MS-275 suggests that selectivity may be 
influenced by the structure of the linker region. We designed structure activity 
relationship (SAR) studies of SAHA to investigate the role of the linker on 
inhibitory activity and selectivity. Moreover, synthesis of a library of SAHA 
analogs would be simple through only several steps since SAHA can be 
synthesized in three steps.21c With these advantages, SAHA analogue libraries 
and SAR studies led us to explore the impact of substituents in the linker region. 
1.6   Specific aims 
Our goal is syntheses of SAHA analogues with substituents on the linker 
region. First of all, small molecule libraries of SAHA analogues would elucidate 
the structural requirements of potent HDAC inhibitors. Second, developing novel 
isoform or class selective inhibitors would be explored by testing the selectivity of 
8 
the SAHA analogues. Third, screening small molecule analogues by using Fluor 
de Lys™ activity assay (Enzo) would allow analyzing potency and selectivity, and 
exploiting veiled interaction between specific cancer formation and selectivity. 
The evaluation of these analogues will be helpful to improve chemotherapeutic 
drug design.  
SAHA achieved the first FDA approval among HDAC inhibitors for 
cutaneous T-cell lymphoma (section 1.3). Cancer patients, however, are still 
suffering from side effects.19 Because side effects may be caused by the fact that 
SAHA is a pan inhibitor, the development of isoform or class-selective inhibitors 
would be critical to understand the relationship between toxicity and individual 
HDAC activity associated with cancer formation. Therefore, the development of 
selective inhibitors has been a significant aim for biological and pharmacological 
studies. Likewise, structure activity relationship (SAR) studies of small molecule 
HDAC inhibitors are required because only limited numbers of the selective 
inhibitors are reported. Therefore, our SAHA analogue syntheses and biological 
activity studies are a fitting starting point to design selective HDAC inhibitor and 
develop better chemotherapy with fewer side effects compared to current pan 
inhibitors.  
 
1.7 Development of isoform or class-selective inhibitors 
Presently, a minority of examples of SAHA analogues containing 
modifications on the carbon linker are reported, in spite of the promising area. 
For example, a few studies of the impact of substituents on the linker have 
9 
explored hydrophobic substituents (Figure 1.5).24 No potency improvement was 
observed in ω-Alkoxy analogues Aa-Ad.
24a In contrast to the ω-Alkoxy analogues 
of SAHA, aminosuberoyl hydroxamic acid analogue Ae is slightly more potent 
than SAHA.24b Furthermore, studies modifying the chain, such as alternating 
chain length and creating an unsaturated chain, were performed as HDAC 
inhibitors.22c, 25 None of the sulfonamides Ba-d (HDAC1 IC50 0.1-1 µM) having 
different chain length and unsaturated chain displayed potency compared to 
highly potent HDAC inhibitors, such as trichostatin A (TSA, IC50 0.005 µM) and 
SAHA (HDAC1 IC50 0.096 µM).
25a However, when polyaminohydroxamic acid 
derivatives Ca, Cb were altered in the polyamine chain and terminal group, these 
analogues promoted increased level of acetylated histones H3, H4 and 
acetylated α-tubulin.25b In case of Ca, the increased level of acetylated α-tubulin 
was significant while Cb had no effect on the acetylation status of α-tubulin. 
Despite the modest change in chain length, distinct differences compared to 
SAHA were observed. As examples of various aryl or cycloalkyl groups in the 
linker, N-hydroxycarboxamides possessing the 1,4-cylohexylene group Da and 
1.4-phenylene group Db were synthesized and showed only modest activities 
(WST-1 IC50 77.9, 38.8 µM).
20c In summary, SAR series of SAHA with 
substituents have been modestly explored. As a result, in our exploratory studies 
of the impact of substituents on the linker, several libraries of SAHA analogues 
were synthesized on the 2, 3, 6, and 7 positions to explore potency and 
selectivity (Figure 1.6).  
 
10 
 
Figure 1.5. Structure Activity Relationship (SAR) Studies: HDAC inhibitors modified at the linker. 
The examples of substituents on the linker (left). The modification of chain length, creation of 
unsaturated chain, and alternation of aryl and cycloalkyl groups (right). 
 
 
Figure 1.6. SAHA analogues containing substituents on the C2, C3, C6, and C7 positions 
 
1.8 Preparation of SAHA analogues containing substituents on the linker 
near the hydroxamic acid 
 
Since the metal binding site may be partially responsible for the potency of 
inhibitors, substituents on the SAHA linker area near hydroxamic acid were 
introduced. Our research group initially reported the synthesis and biological 
activity of C2-SAHA analogues to explore the impact of substituents near 
11 
hydroxamic acid.26 HDAC inhibitory activities of C2-SAHA analogues were 
measured using in vitro fluorescence activity assay kit (Table 1.2).  
Table 1.2. HDAC inhibition by SAHA, MS-275, and the C2-SAHA analogues using HeLa cell 
lysates 
 
Compounds R IC50, Mª 
SAHA  0.090  0.004 
MS-275  3.2  0.1 
 Methyl 134  6 
 Ethyl 449  17 
 n-Propyl 154  7 
 n-Butyl 72  6 
 n-Pentyl 40  3 
 n-Hexyl 60  5 
 Allyl 144  9 
 Propargyl 87  5 
 Benzyl 226  11 
ªValues are the mean of three experiments with standard error given. 
The smallest compound, the methyl variant (IC50 134 µM), displayed 1500 
and 50-fold decreased inhibition compared to SAHA (IC50 0.09 µM) and MS-275 
(IC50 134 µM). Even the most potent pentyl variant showed 439 and 12-fold 
decreased activity compared to SAHA and MS-275. Regardless of the 
substituent size, SAHA analogues modified on the C2 position displayed 
inhibition in the µM range. The high IC50 values of the C2-SAHA analogues 
indicate that only limited steric size is tolerated in the HDAC active site near the 
12 
hydroxamic acid. In other words, bulky substituents near the solvent exposed 
capping group might be more tolerated in the HDAC active site.  
The tendency for significantly decreased inhibition due to substituents 
near the hydroxamic acid proposed designing potent inhibitors. Specifically, the 
poor inhibition of C2-SAHA analogues suggests that analogues with substituents 
positioned closer to the capping group on the C3 position might be more 
tolerated in the HDAC active site. However, we hypothesized that the inhibitory 
activity could be unpredictable because substituents on each linker position 
would have different impact in the HDAC active site channel. Besides, the 
substituents on the C3 position could favorably interact with HDAC active site 
since the 14 Å internal channel near the hydroxamic acid is nearer to C3 carbon 
linker than C2 carbon (Figure 1.4). Therefore, a library of C3-SAHA analogues 
would explore the interaction of the inhibitor with the HDAC active site for potent 
and selective inhibition. The detailed synthesis and biological activity of the 
library of C3-SAHA analogues are described in Chapter 2. 
 
1.9 Preparation of SAHA analogues containing substituents on the linker 
near the capping group 
 
Small molecules with substituents on the capping group or on the linker 
region near the capping group have shown great potency (nM range) and 
moderate selectivity (class-selectivity) (Figure 1.7).27  Specifically, FK-228 
(depsipeptide), which gained FDA approval for cutaneous T-cell lymphoma in 
2009,28 displayed about 300-fold greater potency for HDAC1 and HDAC2 over 
HDAC6.29 Apicidin also displayed 17-230-fold greater potency for HDAC2, 3, and 
13 
8 over HDAC1, 4, 6, 7, and 9.30 Trapoxin B showed HDAC1 selectivity over 
HDAC6.27c The large capping groups in these HDAC inhibitors suggest that 
selectivity is influenced by the capping group substituents. 
Figure 1.7. Known class-selective HDAC inhibitors with bulky groups 
As an example of HDAC selective inhibitor SAR studies with bulky groups 
on the linker near the capping group, compound Ea (IC50 730 nM) containing the 
unusual L-Aoda amino acid was selected and modified (Table 1.3).31 The 
compounds contain a ketone motif, pentyl chain, and indole group instead of 
macrocycle. Although most of compounds lost 2-10 fold activity in the anti-
proliferation assay, the 3-piperid-1-ylpropanamide variant Eh demonstrated 
improved enzyme and cellular activities. As a result, this SAR study altering the 
substituents near the capping group demonstrates the structural requirement 
between inhibitor structures and HDAC functions and directs the design of 
specific cancer drugs. 
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Table 1.3. HDAC1 and PRO (HeLa) inhibition by SAHA, MS-275, Apicidin, the compound Ea, and 
derivatives 
  
Compounds R HDAC1 IC50, nM PRO (HeLa)IC50, nM 
SAHA  27 460 
MS-275  110 1800 
Apicidin  44 290 
Ea  590 730 
Eb Me 930 7600 
Ec 
 
590 3000 
Ed 
 
480 3400 
Ee 
 
540 2500 
Ef 
 
200 1200 
Eg 
 
220 2000 
Eh 
 
190 <390 
 
Since selective inhibition could be influenced by bulky capping groups, 
SAHA analogues with large substituents on the capping group or on the linker 
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area near the capping group have been frequently designed, synthesized, and 
evaluated (Figure 1.8).24a, 32 33  Based on a docking analysis in the crystal 
structures of HDAC7 and HDAC834 of the ω-alkoxy analogue Ab, a T-shape 
arrangement between substituents near the SAHA capping group and the  
lipophilic pockets surrounded by phenylalanine (Phe) residues was found. A π-π 
interaction between the p-methoxybenzyl moieties and Phe208 and Phe152 
residues in the HDAC active site might influence isoform selectivity. Although 
selective inhibition of the ω-alkoxy analogue was not improved, it had superior 
antiproliferative activity. On the other hand, N1-hydroxy-N8-
ferrocenlyoctanediamide, JAHA, displayed picomolar inhibition against class IIa 
HDAC6 (IC50 8 pM) and anticancer action in intact cells (MCF7 cell line). 
Cytotoxicity against a breast cancer cell line indicated that SAHA is the most 
cytotoxic compound (IC50 730nM in MCF7 breast cancer cell lines) compared to 
the JAHA series (IC50 2-5µM in MCF7 breast cancer cell lines). The data suggest 
that the modification of SAHA with bulky groups improves selectivity with 
potency, but displays similar cytotoxicity against the cancer cell line to the parent 
compound in vivo. 
 
ω 
 
Figure 1.8. Examples of SAHA analogues containing substituents on the linker area near 
the capping group (left) and on the capping group (right) 
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1.10 Novel HDAC6-selective inhibitors  
 
We have discussed potential isoform or class-selective inhibitors, and 
common efficacious compounds targeting class I-selectivity.23a, 27c, 29-30 Fewer 
studies have focused on development of class II HDAC selective inhibitors. A 
recent cardiac study reported that stressed myocardium showed catalytic activity 
from the class IIb HDAC, HDAC6.35 Also, overexpression of HDAC6 was 
detected in ovarian and breast cancer tissues.9 Since HDAC6 contains two 
catalytic sites, development and design of HDAC6 selective inhibitor would 
elucidate the function and mechanism of HDAC6. Tubacin is a well-known 
HDAC6 selective inhibitor and displayed 4-fold greater potency for HDAC6 over 
HDAC1 (Figure 1.9).36 Interestingly, the structure of tubacin has similarity with 
class I selective SAHA analogues with bulky substituents at the capping group. 
Slightly different modification on the capping group critically effects selectivity. 
The recent SAR studies of Tubastatin A showed improved selectivity (Figure 
1.9).37 Tubastatin A displayed greater than 1000-fold selectivity against HDAC6 
(IC50 15 nM) compared to HDAC1 (16 µM). An extensive library of tubastatin A 
indicated that tricyclic compounds displayed highly selective inhibition compared 
to other compounds. The structure of Tubastatin A motivates designing new 
isoform selective inhibitors. A detailed discussion of tricyclic compounds will be 
discussed in Chapter 4. 
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Figure 1.9. Structures of HDAC6-selective inhibitors 
 
1.11 Evaluation of SAHA analogues containing substituents on the linker 
near the hydroxamic acid and capping group 
 
Our initial syntheses of libraries of SAHA analogues on the C2 and C3 
position was achieved with substituents containing hydrophobic groups since the 
carbon linker region of SAHA is surrounded by hydrophobic channel (Figure 1.4). 
The data showed that only limited tolerance exists in the HDAC active site near 
the metal binding moiety. In contrast, small molecules with large bulky groups 
have been synthesized near or on the capping group, leading to potent 
inhibitors.21b, 37-38 The outcome suggests that the area near the capping group of 
HDAC inhibitors has great tolerance of steric bulky group in the HDAC active 
sites, confirming our hypothesis. Therefore, our syntheses of libraries of C6 and 
C7-SAHA analogues have introduced bulky substituents near the capping group 
(Chapter 3 and 4). Moreover, the substituents of the SAHA analogues on the C7 
position, which is located closest to the capping group, might allow monitoring 
the interactions between hydrophilic substituents and the HDAC active sites 
18 
since the substituents would be placed on the entrance of the solvent exposed 
area.   
 
1.12 Structure activity relationship (SAR) studies from matrix 
metalloproteinases (MMP), another hydroxamic acid binding protein 
 
Several series of hydrophilic substituents were attached to small molecule 
inhibitors for improving anti-cancer drugs. Natural or medicinal compounds 
containing nitrogen have been designed and used in clinical studies or 
treatments of various diseases because of their outstanding chemical and 
biological activities. For instance, the matrix metalloproteinases (MMPs), like 
HDACs, are relevant enzymes involved in physiologically important processes.39 
Both MMP and HDAC protein are zinc-including metalloproteinases, which 
favorably interact with the hydroxamic acid moiety. Structural information on 
MMPs is related to HDACs because of their relationship as metal-dependent 
proteases. Since proteolysis of the extracellular matrix is found in numerous 
arthritis and cancers40, several MMP inhibitors as therapeutics were discovered 
and modified. Even though HDAC and MMP proteins have similar proteases 
activities, SAR studies of MMP inhibitors with substituents containing nitrogen 
have been more explored than with HDAC inhibitors.  
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Table 1.4. Collagenase 1 (MMP1), gelatinase-A (MMP2), stromelysin 1 (MMP3), gelatinase-B 
(MMP9), collagenase 3 (MMP13) inhibition by N-aryl sulfonyl homocysteine hydroxamate 
analogues 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 IC50, nM 
R MMP1 MMP2 MMP3 MMP9 MMP13 
Fa 
 
51 0.7 1.6 0.2 0.5 
Fb 
 
20 1.2 2.2 0.2 1.1 
Fc 
 
nt 0.30 nt 0.01 nt 
Fd 
 
nt 2.3 3.7 0.5 4.5 
Fe 
 
39 0.4 1.1 0.2 0.4 
Ff  
 
nt 8.82 nt 1.88 nt 
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As one fruitful example, the design, synthesis, and evaluation of MMP 
inhibitors were studied with N-aryl sulfonyl homocysteine hydroxamate inhibitors 
(Table 1.4).41The data showed that hydrophobic aryl groups significantly 
influenced potency. The dipyridyl methyl amide analogue Fe displayed similar 
potency to the monopyridyl analogue Fb while the additional cyclohexyl analogue 
Ff lost potent activity compared to the single cyclohexyl analogue Fc. On the 
other hand, both monopyridyl Fb and dipyridyl Fe analogues displayed greater 
than 20-fold selectivity against MMP2, MMP3, MMP9, and MMP13 compared to 
MMP1. The polarity of the pyridyl derivatives containing nitrogen might be a 
significant factor for MMP selectivity. 
As another representative example, MMP pyridyl derivatives enhanced 
biological inhibitory activity (Table 1.5). Compounds Ha, Hb, and Jb displayed 
poor potency, while inactivity was observed in compounds Hc, I, and Ja. On the 
other hand, the pyridyl group on compound Jb lead to great potency with the 
selective inhibitory activity for MMP9 (IC50 83 nM) against MMP1 (IC50 15000 
nM). The aliphatic substituents on compound Ha and Hb lead to greater inhibitory 
activity compared to analogues with the hydrophilic sustituents (Hc, I, and Ja ).  
Despite the hydrophilicity of pyridyl group, the favorable interaction of the pyridyl 
derivative with MM9 specified that the nitrogen atom may impart selectivity. 
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Table 1.5. Collagenase 1 (MMP1), gelatinase-A (MMP2), stromelysin 1 (MMP3), gelatinase-B 
(MMP9), collagenase 3 (MMP13) inhibition by N-arylsulfonylaziridine hydroxamic acid analogues 
 
Compounds IC50, nM 
 MMP1 MMP2 MMP3 MMP9 MMP13 
G 104 0.7 0.7 2.5 12 
Ha >10 000 617 213 184 380 
Hb 26 400 259 595 203 231 
Hc >100 000 15 000 10 000 4 770 8 775 
I 56 000 98 000 >100 000 >100 000 >100 000 
Ja 50 000 3 600 2 000 500 >100 000 
Jb 15 000 237 164 83 300 
 
1.13 Evaluation of a pyridyl substituent on an HDAC inhibitor, Largazole  
As the most recent example of the enhanced biological activity of an 
HDAC inhibitor containing nitrogen, natural product largazole analogues were 
reported with significant bioactivity (Figure 1.10).42 Largazole was isolated from a 
marine cyanobacterium of the genus Symploca and showed selective activity 
against transformed human mammary epithelial cells (MDA-MB-231, GI50 7.7 
nM) over nontransformed murine mammary epithelial cells (NMuMG, GI50 122 
nM).43 Also, the selectivity was displayed against transformed fibroblastic 
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osteosarcoma cells (U2OS, GI50 55 nM) over nontransformed fibroblasts 
(NIH3T3, GI50 480 nM). Analogues Ka and Kb showed significantly increased 
inhibitory activities for HDAC1 over HDAC6 (80%) while the parent compound 
(largazole) and analogue Kc displayed modest selective inhibition. Investigation 
of potential selective inhibitors has been an attractive target for chemists and 
biologists since specific isoforms might offer opportunities to develop selective 
anti-cancer drugs. With the biological activity trend, a compound containing a 
pyridyl group was synthesized, screened, and discussed in our research 
(Chapter 4). 
 
 
Figure 1.10. Structures of largazole and analogues 
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Currently, SAHA and the other candidates inhibit multiple HDAC 
members. However, isoform-specific HDAC inhibitors are promising targets with 
respect to clinical efficacy due to the fact that broad-spectrum inhibitors have 
demonstrated toxicities in the clinic.44 The mechanism of relative action between 
the selectivity and toxicity of HDAC inhibitors in the clinic is not well-defined, but 
might reveal new mechanism-based therapeutics for cancers. Therefore, several 
studies have reported a link among different HDAC family members, specific 
tumor characteristics, and reduced toxicity profiles.45 Specifically, HDAC inhibitor 
cytotoxicities of pediatric acute myeloid leukemia (AML) cell lines were tested by 
using MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenylterazolium-bromide) 
assays.45e At clinically practicable concentrations, dual HDAC inhibitors that 
inhibited both HDAC1 and HDAC6 displayed the best anti-leukemic activities in 
the four pediatric AML cell lines (THP-1, CMS, Kasumi-1, and MV4-11). As 
mentioned earlier, pre-clinical evaluation of HDAC6-selective inhibitors was 
highlighted in cardiovascular disease.35 Furthermore, investigating HDAC 
inhibitors with hydrophilic substituents including a pyridyl group might enhance 
selective inhibition compared to common pan inhibitors. Even though the function 
or regulation of individual HDAC proteins is still not clear, the development of the 
specific-isoform HDAC protein inhibitors will lead optimal drugs for a variety of 
specific diseases.  
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CHAPTER 2 – SYNTHESIS OF SAHA ANALOGUES MODIFIED AT THE C3 
POSITION 
2.1 Rationale for design of the SAHA analogues containing substituents 
on the C3 position  
Inhibitor binding to a zinc atom at the bottom of the active site plays a 
critical role in potency. Therefore, introducing substituents near hydroxamic acid 
would help understand structural requirements of HDAC inhibitors. The SAR 
study of SAHA on the linker area is relatively unexplored, in spite of it is being a 
fruitful potential area (Chapter 1.5). Especially, there is the possibility to develop 
isoform selective inhibitors through designing a library of SAHA analogues on the 
linker. When SAHA is present in HDAC active site, it has been observed that the 
linker is tightly surrounded by a hydrophobic tunnel (Figure 1.4). We theorized 
that hydrophobic substituents attached at the linker would display better 
interaction with the HDAC active site than hydrophilic substituents. 
To explore the impact of substituents in the liker area, we previously 
studied SAHA analogues with hydrophobic substituents attached on the C2 
position (Figure 2.1).26 In this case, inhibitor potency was significantly reduced 
regardless of substituent size. The lack of potency of the C2-SAHA analogues 
indicates that limited flexibility exists in the HDAC active site near the hydroxamic 
acid group. In 
contrast, high 
potency (nM 
range) HDAC 
 
Figure 2.1. Structures of SAHA analogues containing substituents on the 
C2 and C3 position 
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inhibitors have been created with bulky substituent near the solvent-exposed 
region.27c, 31, 46 Therefore, we proposed that HDAC proteins would be more 
tolerant of SAHA analogues containing substituents positioned closer to the 
solvent exposed surface. 
To systematically probe the impact of substituents present in the linker, 
SAHA analogues with substituents on the C3 position were synthesized (Figure 
2.1).47 We theorized that analogues with substituents attached at the C3 position 
would display more potent inhibition compared to analogues with C2 substituents 
due to their location closer to the solvent-exposed region. 
 
2.2 Initial synthesis 
We initially synthesized the C3-SAHA n-butyl analogue 1a, as shown 
Scheme 1. The ring of commercially available ε-caprolactone 2 was opened with 
aniline and trimethyl aluminum to give alcohol 3, which was subjected to Swern 
oxidation to give aldehyde 4. The Horner-Wadsworth-Emmons reaction with 
trimethyl phosphonoacetate gave the corresponding α,β-unsturated ester 5. The 
(E) and (Z)-isomers of ester 5 were separated by column chromatography and 
then individually treated with a copper (I) bromide dimethylsulfide complex to give 
the n-butyl ester 6a. Saponification of 6a gave carboxylic acid 7, which was 
coupled with O-benzyl-protected hydroxamine. O-benzyl-protected hydroxamic 
acid 8 was deprotected by hydrogenolysis to give the C3-n-butyl SAHA 1a.  
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Scheme 2.1. Initial synthesis of C3-SAHA analogue (n-butyl derivative 1a) 
 
2.3 Optimized synthesis 
To create the remaining C3-SAHA analogues, several aspects of the 
synthesis were improved (Scheme 2.2).  
 
Scheme 2.2. Optimized synthesis of C3-SAHA analogues 1d -1e 
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First, the 1,4-conjugate addition reaction (5 to 6) was performed using a 
mixture of (E) and (Z) isomers without the separation. Second, we found that 
when preparing compound 6e from methyl lithium, no addition product was 
observed. However, addition of trimethylsilane chloride (TMSCl) to the reaction 
gave excellent yield.48 With this success, TMSCl was included in the addition 
reaction with all remaining analogues. Finally, we used a direct, one-step 
conversion of ester 6 to the final product 1. In the synthesis of C3-n-butyl SAHA 
1a, a benzyl-protected hydroxamic acid intermediate 8 was used en route to the 
hydroxamic acid final product, as previously reported (Scheme 1).26 However, 
40% yield after three steps (saponification, coupling O-benzyl hydroxylamine, 
and benzyl deprotection) was unsatisfying. The direct conversion using 
neutralized hydroxylamine in methanol was more efficient compared to the three-
step conversion and was employed for all remaining analogues (1b-1e). Using 
theses modified conditions, the phenyl, ethyl, vinyl, and methyl analogues 1b-1e 
were synthesized (Scheme 2.2). 
 
2.4 Biological analysis 
The inhibitory activities of the C3-SAHA were measured using Fluor de 
Lys™ in vitro fluorescence activity assay kit (Biomol) using HeLA cell lysates as 
the source of HDAC activity by Dr. Sujith Weerasinghe (Table 2.1).26  
The methyl variant 1e was the most potent analogue, displaying an IC50 of 
350 nM, which is only 4-fold less potent than SAHA (90 nM). Theses results 
indicate that the active site of HDAC proteins can accommodate a small methyl 
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substituent at the C3 position. The potency of the remaining analogues 
decreased with increasing size of the C3 substituent. The n-butyl and phenyl 
analogues (1a and 1b) displayed the weakest inhibitory activity (184 µM and 73 
µM, respectively). Interestingly, the ethyl-substituted analogue 1c displayed 91-
fold decreased activity compared to the methyl analogue 1e, despite containing 
only one additional methylene. Likewise, the vinyl analogue 1d showed 
significantly reduce activity compared to the methyl analogue 1e. In total, the 
data indicated that a C3-methyl substituted SAHA analogue maintains nM 
potency, but substituents larger than methyl result in a reduction in potency. 
 
Table 2.1. HDAC inhibition by SAHA, MS-275, and the C3-SAHA analogues using HeLa cell 
lysates 
Compounds R IC50, Mª 
SAHA  0.090  0.004 
MS-275  3.2  0.1 
1a n-Butyl 184  14 
1b Phenyl 73  14 
1c Ethyl 32  4 
1d Vinyl 15  1 
1e Methyl 0.350  0.05 
ªValues are the mean of three experiments with standard error given. 
 
The inhibition results are consistent with the hypothesis that linker 
substituents are accommodated in the HDAC active site when positioned closer 
to the solvent exposed capping group of SAHA. While the C3-methyl analogue 
displayed potency comparable to SAHA (4-fold reduced), the previously reported 
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C2-methyl analogue (IC50 of 134 µM) displayed 1488-fold reduced activity versus 
SAHA.26 Interestingly, the C3-n-butyl variant 1a is less potent (184 µM IC50) than 
the previously reported C2-n-butyl analogue (72 µM IC50),
26 suggesting that the 
area of the HDAC active site near the C2 and C3 linker position displays 
structural differences. 
We next tested the isoform selectivity of the C3-SAHA analogues. 
Creating isoform selective HDAC inhibitors has been challenging.20 However, the 
availability of selective inhibitors would provide powerful chemical tools to dissect 
the individual functions of the HDAC isoforms, in addition to providing lead 
antitumor drug candidates. To assess the isoform selectivity of the C3-SAHA 
analogues, HDAC1 and HDAC3 representing class I and HDAC6 representing 
class II were tested at a single concentration near to their IC50 values using the 
Fluor de Lys™ kit (Figure 2.2). As expected, SAHA almost equally inhibited 
HDAC1, HDAC3, and HDAC6.30 In contrast, the ethyl variant 1c showed greater 
potency for HDAC6 over HDAC1 and HDAC3 at 32 µM. The butyl, phenyl, and 
vinyl variants (1a, 1b, and 1c) also showed similar, although more modest, 
preference for HDAC6 over HDAC3. 
30 
 
Figure 2.2. Screen of C3-SAHA analogues against HDAC1, HDAC3, and HDAC6 with                                                             
125 nM SAHA, 32 µM 1a-d, and 375 nM 1e.  
 
To more rigorously assess the selectivity observed in the initial screen, we 
determined the IC50 values of the C3-ethyl variant 1c because it displayed the 
most promising results in the initial screen. The C3-ethyl analogue 1c displayed 
12-fold selectivity for HDAC6 over HDAC3 and 3-fold selectivity for HDAC6 over 
HDAC1 (Table 2.2). In addition, it displayed selectivity within class I, with 4-fold 
preference for HDAC1 over HDAC3. As a control, SAHA displayed similar 
inhibitor activity against the isoform, as expected (Table 2.2).30 The isoform 
selectivity analysis shows that a substituent on the C3 position can transform 
SAHA from non-selective inhibitor to an HDAC6-selective one. As a comparison, 
the HDAC6-selective inhibitor tubacin displays 7-fold selectivity for HDAC6 over 
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HDAC149 and has been used widely in cell biology studies.50 Therefore, the data 
indicate that isoform selective SAHA analogues can be generated by attaching a 
substituent to the linker chain. 
 
Table 2.2. IC50 values of SAHA and the C3-ethyl SAHA variant 1c for HDAC1, HDAC3, and 
HDAC6  
 
SAHA analogues with substituents on the C3 position displayed HDAC6-
selective inhibition, in contrast to the broad-spectrum inhibitor SAHA. These 
results reveal that small structural changes in the linker region of SAHA can 
significantly influence selectivity. 
 
2.5 Experimentals 
2.5.1 General methods 
Starting materials, reagents, and solvents for reactions obtained from 
Acros, Sigma-Aldrich, and VWR were used as purchased. Moisture-sensitive 
reactions were performed under argon with dried glassware and dry solvent. 
Iron-sensitive reactions were performed with acid-washed glassware and were 
purified with silica gel that was washed with 6M aqueous hydrochloric acid 
through at least 3 times. Thin-layer chromatography with 60Å, 250µm Partisil® 
K6F fluorescent indicator plates was used to monitor reactions.  Flash 
Compound IC50/µM
a
 
HDAC1 HDAC3 HDAC6 
SAHA 0.096 ±  0.016 0.146 ± 0.012 0.074 ±  0.009 
1c 22 ± 2 97 ± 6 8 ± 1 
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chromatography was performed with 60 Å, 230-400 mesh silica gel (Whatman).  
Solvents were removed by rotary evaporation (Büchi Rotavapor R-114 and Büchi 
Waterbath B-480) and a vacuum pump (Welch Vaccum, Thomas Industries, 
Inc.). NMR spectra were recorded in CDCl3 or CD3OD using a Varian Unity 300 
MHz or Varian L900 400 MHz.  Mass spectrometric analysis was performed at 
Wayne State University’s Central Instrumentation facility using a Waters LCT 
Premier XE ESI-LC-MS TOF or a Waters GCT EI-TOF.  IR spectra were 
recorded in Jasco FT/IR – 4100. HPLC analysis was performed with a Waters 
1525 Binary HPLC pump, Waters 2998 Photodiode Array detector, and a 
Symmetry® Reverse Phase C18 5µm column (4.6x150 mm Diameter) using a 
gradient of 10% Buffer A to 90% Buffer B over 20 min (Buffer A = water with 
0.1% TFA; Buffer B = HPLC grade acetonitrile) at 1.0 mL/min at room 
temperature.  
2.5.2 Experimental Procedures and Compound Characterization 
 
5-Hydroxy-N-phenylpentanamide (3). Trimethyl aluminum (1.88 mL, 3.75 
mmol) and aniline (0.34 mL, 3.75 mmol) were stepwise added to a solution of ε–
caprolactone (0.28 mL, 2.5 mmol) in dry THF (25 mL) at 0ºC. The mixture was 
stirred and warmed to room temperature over 3 h. The reaction mixture was 
quenched by a dropwise addition of 1.0 M aqueous hydrochloric acid until 
evolution of gas was not observed. The mixture was subsequently diluted with 
anhydrous diethyl ether (10 mL) and washed with distilled water (5 mL). The 
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aqueous layer was extracted with diethyl ether (10 mL) at least 3 times. The 
organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The 
residue was purified by column chromatography (20% acetone/CH2Cl2) on silica 
gel to give 3 (469 mg, 91%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.41 (m, 2H), 
1.58 (m, 2H), 1.71 (m, 2H), 2.39 (bs, 1H), 2.60 (m, 2H), 3.59 (m, 2H), 7.10 (t, 
1H), 7.29 (t, 2H), 7.59 (d, 2H), 7.90 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-
D): 25.8, 25.9, 32.1, 39.1, 61.9, 120.2, 124.1, 128.9, 138.8, 173.5; IR: 3298, 
3136, 3063, 2936, 2863, 1663, 1599, 1544, 1498, 1442, 1309, 908, 730 cm-1; 
HRMS ( EI-TOF, m/z): found [M] 207.1259, calc. for C12H17NO2, 207.1259. 
 
6-Oxo-6-(phenylamino)hexanal (4). To a solution of DMSO (1.75 mL, 24.62 
mmol) in CH2Cl2 (75 mL) was added oxalyl chloride (5.60 mL, 11.19 mmol) 
dropwise and then 5-hydroxy-N-phenylpentanamide 3 (1.55 g, 7.46 mmol) 
stepwise at -78ºC. The reaction mixture was stirred for 45 min before 
triethylamine (TEA, 7.05 mL, 50.73 mmol) was added dropwise at -78 ºC. The 
mixture was warmed to room temperature and stirred for an additional 1 h. The 
reaction mixture was quenched by adding distilled water (75 mL). The mixture 
was diluted with CH2Cl2 (25mL) and washed with 1.0 M aqueous hydrochloric 
acid (25 mL), an aqueous solution of saturated NaHCO3 (100 mL), and brine (100 
mL). The organic layer was dried over anhydrous Na2SO4, filtered, and 
concentrated. The residue was purified by column chromatography 
(ether:petroleum ether 4:1) on silica gel to give 4 (1.25 g, 81%). 1H-NMR (δ, ppm, 
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CHLOROFORM-D): 1.67-1.72 (m, 4H), 2.36 (t, 2H), 2.47 (t, 2H), 7.07 (t, 1H), 
7.28 (t, 2H), 7.52 (d, 2H), 9.74 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 
21.7, 25.1, 37.4, 43.8, 120.2, 124.5, 129.2, 138.2, 171.3, 202.7; IR: 3305, 3198, 
3140, 3059, 2940, 2866, 2826, 2726, 1721, 1664, 1599, 1543, 1498, 1442, 1310, 
909, 730 cm-1; HRMS (EI-TOF, m/z): found [M] 205.1106, calc. for C12H15NO2, 
205.1103. 
 
8-Oxo-8-(phenylamino)-oct-2-enoate (5). To a solution of NaH (435 mg, 10.88 
mmol) in THF (64 mL) was added trimethyl phosphonoacetate (1.6 mL, 10.88 
mmol) dropwise at 0 ºC and the mixture was stirred for 15 min. To the solution 
was added 6-oxo-6-(phenylamino)hexanal 4 (1.3 g, 6.40 mmol) at -78 ºC and the 
mixture was stirred for 15 min. The mixture was allowed to warm to room 
temperature and stirred for an additional 1 h. The mixture was quenched by 
addition of an aqueous solution of saturated NH4Cl until evolution of gas was not 
observed. The mixture was washed with distilled H2O (64 mL) at least 3 times. 
The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. 
The residue was purified by column chromatography (ether:petroleum ether 2:3) 
on silica gel to give 5 (E-isomer; 1,136 mg, 68%, Z-isomer; 289mg, 17%).  For 
preparation of butyl derivative 6a, the E and Z isomers were used separately, as 
described below.  For the other derivatives 6b-e, the E isomer alone or a 
mixture of E/Z isomers was used. Synthesis of the mixture of E/Z isomers was 
similar that of each isomer, except the following reagents were used:  trimethyl 
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phosphonoacetate (391 mL, 2.57 mmol) in THF (15 mL), NaH (102 mg, 4.27 
mmol) and 6-oxo-6-(phenylamino)hexanal 4 (310 mg, 1.51 mmol). The residue 
was purified by column chromatography (ether:petroleum ether 2:3) on silica gel 
to give 5 (E+Z) (391 mg, 99%).  (Z)-isomer 1H-NMR (δ, ppm, CHLOROFORM-
D): 1.54 (m, 2H), 1.76 (m, 2H), 2.38 (t, 2H), 2.68 (q, 2H), 3.71 (s, 3H), 5.79 (d, 
1H, J=180 Hz), 6.24 (m, 1H), 7.09 (t, 1H), 7.29 (m, 2H), 7.51 (d, 2H), 7.64 (s, 
1H); (E)-isomer 1H-NMR (δ, ppm, CHLOROFORM-D): 1.54 (m, 2H), 1.76 (m, 
2H), 2.21 (q, 2H), 2.38 (t, 2H), 3.71 (s, 3H), 5.82 (d, 1H, J=448 Hz), 6.94 (m, 1H), 
7.08 (t, 1H) 7.27 (m, 2H), 7.49 (d, 2H); (E+Z)-isomer 13C-NMR (δ, ppm, 
CHLOROFORM-D): 25.3, 27.8, 32.2, 37.5, 51.7, 120.1, 121.5, 124.3, 129.2, 
138.2, 149.2, 150.4, 167.4, 171.3; IR: 3674, 3308, 2950, 1721, 1658, 1600, 
1541, 1498, 1441, 1310, 910, 756, 693 cm-1; HRMS (EI-TOF, m/z): found [M] 
261.1361, calc. for C15H19NO3, 261.1365. 
 
 
8-Oxo-8-(phenylamino)-3-n-butyloctanoate (6a). To a solution of Cu(I)Br·SMe2 
(880 mg, 4.28 mmol) in THF (14.3 mL) was added n-butyl lithium (5.35 mL, 8.56 
mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The reaction 
mixture was cooled to -78 ºC before addition of (Z)-8-oxo-8-(phenylamino)-oct-2-
enoate 5 (373 mg, 1.43 mmol, Z isomer only) at -78 ºC. The reaction was stirred 
for 3 h at -78 ºC to room temperature and then quenched by addition of 1.0 M 
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aqueous hydrochloric acid until a color of the mixture changed to blue (CuCl2(aq)). 
The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. 
The residue was purified by column chromatography (ether:petroleum ether 2:3) 
on silica gel to give 6a (378 mg, 83% from the Z isomer). The synthesis starting 
from the E isomer of 5 was similar to that above except the following reagents 
were used: Cu(I)Br·SMe2 (470 mg, 2.28 mmol) in THF (11 mL), n-butyl lithium 
(2.85 mL, 4.56 mmol), and (E)-8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 
0.76 mmol, E isomer only) at -78 ºC. Chromatography gave 6a (117 mg, 48% 
from the E isomer). 1H-NMR (δ, ppm, CHLOROFORM-D): 0.87 (t, 3H), 1.24-1.32 
(m, 10H), 1.70 (m, 2H), 1.84 (m, 1H), 2.21 (m, 2H), 2.33 (t, 2H), 3.65 (s, 3H), 
7.07 (t, 1H), 7.29 (t, 2H), 7.51 (d, 2H), 7.62 (bs, 1H); 13C-NMR (δ, ppm, 
CHLOROFORM-D): 14.3, 23.1, 25.9, 26.1, 29.0, 33.5, 33.7, 35.0, 37.7, 39.1, 
51.7, 120.0, 124.3, 129.1, 138.3, 171.7, 174.4; IR: 3303, 3197, 3137, 3059, 
2928, 2857, 1737, 1662, 1600, 1542, 1499, 1441, 1309, 903, 755, 693 cm-1; 
HRMS (EI-TOF, m/z): found [M] 319.2143, calc. for C19H29NO3, 319.2147. 
 
8-Oxo-8-(phenylamino)-3-phenyloctanoate (6b). To a solution of Cu(I)Br·SMe2 
(945 mg, 4.59 mmol) in THF (7.7 mL) was added phenyl lithium (4.59 mL, 9.19 
mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The reaction 
mixture was cooled to -78 ºC. To the solution was added trimethylsilyl chloride 
(TMSCl, 1.76 mL, 13.78 mmol) dropwise and then 8-oxo-8-(phenylamino)-oct-2-
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enoate 5 (200 mg, 0.77 mmol, only E isomer) stepwise at -78 ºC.  Only the E 
isomer of 5 was used because the presence of the Z isomer complicated 
purification. The mixture was stirred for 3 h at -78 ºC and then quenched by 
addition of an aqueous solution of NH4Cl:NH4OH (1:1) until a color of the mixture 
turned to blue ((NH3)4CuCl2(aq)). The mixture was washed with the aqueous 
solution of NH4Cl:NH4OH (1:1) (7.7 mL). The organic layer was dried over 
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by 
column chromatography (ether:petroleum ether 1:1) on silica gel to give 6b (154 
mg, 59%).  1H-NMR (δ, ppm, CHLOROFORM-D): 1.22 (m, 2H), 1.62-1.68 (m, 
4H), 2.23 (m, 2H), 2.59 (m, 2H), 3.07 (m, 1H), 3.57 (s, 3H), 7.06 (t, 1H), 7.19 (m, 
3H), 7.29 (m, 4H), 7.47 (d, 2H), 7.53 (bs, 1H); 13C-NMR (δ, ppm, 
CHLOROFORM-D): 25.6, 27.0, 35.8, 37.6, 41.8, 42.1, 51.8, 120.1, 124.4, 126.8, 
127.6, 128.7, 129.1, 138.3, 144.0, 171.6, 173.2; IR: 3310, 3045, 2924, 2857, 
1698, 1603, 1600, 1456, 1378, 1265, 910, 755, 735 cm-1. HRMS (EI-TOF, m/z): 
found [M+Na] 362.1732, calc. for C21H25NO3Na, 362.1732; 
 
8-Oxo-8-(phenylamino)-3-ethyloctanoate (6c). The synthesis was similar that 
of 6b except the following reagents were used: Cu(I)Br·SMe2 (945 mg, 4.59 
mmol) in THF (7.7 mL), ethyl lithium (5.41 mL, 9.19 mmol), TMSCl (1.76 mL, 
13.78 mmol), and 8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 0.77 mmol, E 
and Z mixture).  The product was purified by column chromatography 
(ether:petroleum ether 1:1) on silica gel to give 6c (215 mg, 96%). 1H-NMR (δ, 
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ppm, CHLOROFORM-D): 0.85 (t, 3H), 1.23-1.38 (m, 6H), 1.9 (m, 2H), 1.78 (m, 
1H), 2.21 (m, 2H), 2.32 (t, 2H), 3.64 (s, 3H), 7.07 (t, 1H), 7.28 (t, 2H), 7.51 (d, 
2H), 7.77 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 11.0, 25.9, 26.2, 26.5, 
33.1, 36.5, 37.7, 38.7, 51.7, 120.1, 124.3, 129.1, 138.4, 171.8, 174.4; IR: 3675, 
3308, 3198, 3139, 3061, 2960, 2934, 1734, 1665, 1601, 1543, 1499, 1442, 1309, 
911, 756, 733 cm-1; HRMS (EI-TOF, m/z): found [M] 291.1830, calc. for 
C17H25NO3, 291.1834. 
 
8-Oxo-8-(phenylamino)-3-vinyloctanoate (6d). The synthesis was similar to 
that of 6b except the following reagents were used: CuI  (875 mg, 4.59 mmol) in 
THF (7.7 mL), vinyl magnesium bromide (6.56 mL, 4.59 mmol), TMSCl (1.76 mL, 
13.78 mmol), and 8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 0.77 mmol, 
only E isomer). Only the E isomer of 5 was used because the presence of the Z 
isomer complicated purification. The product was purified by column 
chromatography (ether:petroleum ether 1:1) on silica gel to give 6d (191 mg, 
86%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.33 (m, 2H), 1.39 (m, 2H), 1.70 (m, 
2H), 2.30-2.34 (m, 4H), 2.50 (m, 1H), 3.64 (s, 3H), 5.00 (m, 2H), 5.57 (m, 1H), 
7.08 (t, 1H), 7.29 (t, 2H), 7.50 (d, 2H), 7.57 (bs, 1H); 13C-NMR (δ, ppm, 
CHLOROFORM-D): 25.6, 26.7, 34.1, 37.7, 40.1, 40.4, 51.7, 115.6, 120.0, 124.4, 
129.2, 138.3, 140.9, 171.7, 173.3; IR: 3315, 3199, 3138, 3076, 2939, 2859, 
1737, 1601, 1543, 1499, 1442, 1308, 915, 755 cm-1; HRMS (EI-TOF, m/z): found 
[M] 312.1564, calc. for C17H23NO3Na, 312.1576. 
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8-oxo-8-(phenylamino)-3-methyloctanoate (6e). The synthesis was similar that 
of 6b except the following reagents were used: Cu(I)Br·SMe2 (945 mg, 4.59 
mmol) in THF (7.7 mL), methyl lithium (5.74 mL, 9.19 mmol), TMSCl (1.76 mL, 
13.78 mmol) and 8-oxo-8-(phenylamino)-oct-2-enoate 5 (200 mg, 0.77 mmol, E 
and Z mixture). The residue was purified by column chromatography 
(ether:petroleum ether 2:3) on silica gel to give 6e (232 mg, 99%). 1H-NMR (δ, 
ppm, CHLOROFORM-D): 0.92 (d, 3H), 1.21-1.40 (m, 4H), 1.72 (m, 2H), 1.95 (m, 
1H), 2.11-2.36 (m, 4H), 3.66 (s, 3H), 7.09 (t, 1H), 7.31 (t, 2H), 7.51 (d, 2H), 7.68 
(bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 19.9, 25.8, 26.6, 30.3, 36.3, 
37.7, 41.7, 51.7, 120.0, 124.3, 129.2, 138.3, 171.7, 174.1; IR: 3305, 3197, 3137, 
3060, 2931, 2859, 1738, 1662, 1600, 1539, 1499, 1442, 1309, 1008, 902, 756 
cm-1; HRMS (EI-TOF, m/z): found [M] 277.1678, calc. for C16H23NO3, 277.1678. 
 
3-n-Butyl-N1-hydroxyl-N8-phenyloctanoic acid (7). To a solution of 8-oxo-8-
(phenylamino)-3-n-butyloctanoate 6a (492mg, 1.54mmol) was added NaOH 
(6.16 mL, 30.79 mmol) in MeOH (15 mL) and the mixture was refluxed overnight. 
The reaction was quenched by adding conc. aqueous hydrochloric acid (up to pH 
6) and then extracting with H2O (5 mL) and ethyl acetate (20 mL). The organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue 
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was purified by column chromatography (20% acetone/CH2Cl2) on silica gel to 
give 7 (189 mg, 40%). 1H-NMR (δ, ppm, CHLOROFORM-D): 0.87 (t, 3H), 1.27-
1.37 (m, 10H), 1.63 (m, 2H), 1.86 (m, 1H), 2.17-2.36 (m, 4H), 7.09 (t, 1H), 7.30 (t, 
2H), 7.50 (d, 2H), 7.71 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 14.3, 
23.1, 25.9, 26.1, 29.0, 33.5, 33.7, 35.0, 37.7, 39.1, 120.2, 124.5, 129.1, 138.2, 
172.1, 179.5; IR: 3306, 3195, 3137, 3060, 2928, 2858, 1705, 1662, 1599, 1543, 
1499, 1442, 1309, 907, 755, 692 cm-1; HRMS (EI-TOF, m/z): found [M] 305.1993, 
calc. for C18H27NO3, 305.1991. 
 
3-n-Butyl-N1-benzyloxy-N8-phenyloctanediamide (8). O-benzylhydroxylamine 
hydrochloride salt (144g, 0.9mmol) and Na2CO3 (47g, 0.45mmol) were dissolved 
in distill H2O (9 mL), extracted with diethyl ether (9 mL) and concentrated. TBTU 
(289g, 0.9 mmol) and 3-n-butyl-N1-hydroxyl-N8-phenyloctanoic acid 7 (189mg, 
0.6mmol) were added to the neutralized O-benzylhydroxylamine residue in 
CH3CN (6mL). The reaction mixture was stirred overnight at room temperature 
and then quenched by adding NaHCO3 (6 mL). The mixture was extracted with 
H2O and DCM (1:1). The organic layer was dried over anhydrous Na2SO4, 
filtered, and concentrated. The residue was purified by column chromatography 
(10% acetone/DCM) on silica gel to give 8 (121 mg, 49%). 1H-NMR (δ, ppm, 
CHLOROFORM-D): 0.86 (t, 3H), 1.22-1.35 (m, 12H), 1.66 (m, 1H), 1.94 (m, 2H), 
2.30 (m, 2H), 5.29 (s, 2H), 7.07 (t, 1H), 7.28 (m, 7H), 7.55 (d, 2H), 8.12 (bs, 1H); 
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13C-NMR (δ, ppm, CHLOROFORM-D): 14.3, 23.1, 25.3, 25.7, 29.1, 32.5, 33.7, 
35.0, 37.2, 37.9, 78.4, 120.1, 124.3, 128.8, 129.1, 129.4, 138.5, 171.0, 172.3; IR: 
3724, 3195, 3140, 3064, 2929, 2858, 1656, 1620, 1600, 1544, 1498, 1442, 1380, 
1309, 1253, 1046, 1030, 975,  911, 734, 695 cm-1; HRMS (EI-TOF, m/z): found 
[M] 410.2566, calc. for C25H34N2O3, 410.2569. 
 
3-n-Butyl-N1-hydroxyl-N8-phenyloctandiamide (1a). To a solution of 3-n-butyl-
N1-benzyloxy-N8-phenyloctanediamide 8 (121 mg, 0.3 mmol) in methanol (3mL) 
was added 20% Pd(OH)2/C (32 mg, 0.03 mmol) in an acid-washed 25mL round-
bottom flask and the reaction mixture was purged with H2 (g) for 30 s. The reaction 
solution was stirred under H2 (g) for 30 min and then filtered through a plug of 
Celite with MeOH (9 mL). The filtrate was concentrated to give 1a (89 mg, 92%) 
as a clear oil.   1H-NMR (δ, ppm, METHANOL-D4): 0.88 (t, 3H), 1.28-1.39 (m, 
10H), 1.68 (m, 2H), 1.86 (m, 1H), 2.02 (d, 2H), 2.37 (t, 2H), 7.07 (t, 1H), 7.28 (t, 
2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4):  13.2, 22.8, 25.9, 28.6, 
33.1, 33.2, 35.0, 36.7, 37.6, 120.1, 123.9, 128.6, 138.7, 171.4, 173.5; IR: 3384, 
3044, 2929, 2858, 1640, 1600, 1546, 1499, 1468, 1309, 976, 903, 755, 693 cm-1; 
HRMS (EI-TOF, m/z): found [M] 320.2108, calc. for C18H28N2O3, 320.2100; HPLC 
analytical purity analysis: 92%. 
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3-Phenyl-N1-hydroxyl-N8-phenyloctandiamide (1b). To a solution of 
NH2OH∙HCl (315 mg, 4.54 mmol) in methanol (4.5 mL) was added KOH (509 mg, 
9.08 mmol) at 0 ˚C in an acid-washed 25mL round-bottom flask.  After stirring 
for 20 min, 8-oxo-8-(phenylamino)-3-phenyloctanoate (6b) (154 mg, 0.45 mmol) 
was added and the mixture was stirred for 8 h at 0°C. The reaction mixture was 
quenched by adding 1mL of distilled water and adjusting to pH 6 by adding 
concentrated aqueous hydrochloric acid. The mixture was diluted with 30 mL of 
ethyl acetate, and washed with distilled water. The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated. The residue was purified by 
column chromatography (10% methanol/CH2Cl2) on acid-washed silica gel to 
give 1b (48 mg, 31%).  1H NMR (δ, ppm, METHANOL-D4): 1.22 (m, 2H), 1.55-
1.73 (m, 4H), 2.25-2.43 (m, 4H), 3.09 (m, 1H), 7.06 (t, 1H), 7.12-7.29 (m, 7H), 
7.47 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4):  25.6, 26.8, 35.4, 36.6, 40.2, 
42.3, 120.1, 124.0, 126.4, 127.5, 128.3, 128.5, 138.6, 143.9, 170.1, 173.4; IR: 
3256, 3030, 2932, 2860, 2559, 1646, 1600, 1545, 1499, 1468, 1442, 1420, 1372, 
1310, 1253, 906, 758 cm-1; HRMS (EI-TOF, m/z): found [M] 340.1789, calc. for 
C20H24N2O3, 340.1787; HPLC analytical purity analysis: 91%. 
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3-Ethyl-N1-hydroxyl-N8-phenyloctandiamide (1c). A similar procedure to that 
for 1b was used, except for the following reagents: NH2OH∙HCl (520 mg, 7.48 
mmol) in methanol (7.4 mL), KOH (839 mg, 14.96 mmol), 8-oxo-8-(phenylamino)-
3-ethyloctanoate (6c) (218 mg, 0.75 mmol) and stirring for 4 h. In this case, the 
product was purified by column chromatography (8 % methanol/CH2Cl2) on acid-
washed silica gel to give 1c (130 mg, 60%).  1H-NMR (δ, ppm, METHANOL-D4): 
0.88 (t, 3H), 1.28-1.41 (m, 6H), 1.68 (m, 2H), 1.81 (m, 1H), 2.01 (m, 2H), 2.36 (t, 
2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4):  
9.8, 25.9, 32.6, 36.5, 36.7, 37.1, 120.1, 123.9, 128.6, 138.7, 171.4, 173.5; IR: 
3857, 3404, 2935, 2862, 1649, 1600, 1544, 1501, 1469, 1311, 978, 904, 758, 
691 cm-1; HRMS (EI-TOF, m/z): found [M-H] 292.1718, calc. for C16H23N2O3, 
292.1709; HPLC analytical purity analysis: 99%. 
 
 
3-Vinyl-N1-hydroxyl-N8-phenyloctandiamide (1d). A similar procedure to that 
for 1b was used, except for the following reagents: NH2OH∙HCl (456 mg, 6.57 
mmol) in methanol (6.6 mL), KOH (737 mg, 13.13 mmol), 8-oxo-8-(phenylamino)-
3-vinyloctanoate (6d) (190 mg, 0.66 mmol), and stirring for 6 h. In this case, the 
product was purified by column chromatography (8 % methanol/CH2Cl2) on acid-
washed silica gel to give 1d (83 mg, 43%).  1H-NMR (δ, ppm, METHANOL-D4): 
1.33-1.47 (m, 4H),1.70 (m, 2H), 2.08 (m, 2H), 2.35 (t, 2H), 2.50 (m, 1H), 5.00 (q, 
2H), 5.58 (m, 1H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, 
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METHANOL-D4):  25.6, 26.5, 33.9, 36.6, 38.3, 40.8, 115.0, 120.1, 124.0, 128.6, 
138.7, 140.7, 170.3, 173.4; IR: 3299, 3079, 2931, 1647, 1600, 1542, 1500, 1442, 
1312, 920, 758, 692 cm-1; HRMS (EI-TOF, m/z): found [M+Na] 313.1533, calc. 
for C16H22N2O3Na, 313.1528; HPLC analytical purity analysis: 94%. 
 
 
3-Methyl-N1-hydroxyl-N8-phenyloctandiamide (1e). A similar procedure to that 
for 1b was used, except for the following reagents: NH2OH∙HCl (533 mg, 7.67 
mmol) in methanol (7.7 mL), KOH (860 mg, 15.33 mmol), 8-oxo-8-(phenylamino)-
3-methyloctanoate (6e) (213 mg, 0.77 mmol), and stirring for 2 h. In this case, the 
product was purified by column chromatography (10 % methanol/CH2Cl2) on 
acid-washed silica gel to give 1e (160 mg, 75%). 1H-NMR (δ, ppm, METHANOL-
D4): 0.93 (d, 3H), 1.28 (m, 2H), 1.40 (m, 2H), 1.68 (m, 2H), 1.89 (m, 2H), 2.07 
(m, 1H), 2.36 (t, 2H), 7.07 (t, 1H), 7.28 (t, 2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, 
METHANOL-D4):  18.6, 25.8, 26.4, 30.4, 36.2, 36.7, 40.1, 120.1, 123.9, 128.6, 
138.7, 171.1, 173.4; IR: 3198, 2927, 2855, 2359, 1657, 1598, 1544, 1499, 1443, 
755, 691 cm-1; HRMS (EI-TOF, m/z): found [M] 278.1635, calc. for C15H22N2O3, 
278.1630; HPLC analytical purity analysis: 98%. 
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2.6 HDAC high-throughput assay 
2.6.1 Fluorescence activity assay for libraries of SAHA analogues 
A number of HDAC inhibitors have been attractive targets as 
chemotherapeutic drugs due to that the overexpression activity of HDAC, which 
leads malignant diseases, as discussed (Section 1.2). Our research is also 
focused on development of novel HDAC inhibitors based on SAHA. Therefore, 
SAHA analogues were screened compared to SAHA using a Fluorescence high-
throughput assay. The deacetylase activity was measured using the Fluor de 
Lys® activity assay (Enzo) using the manufacturer’s protocol(Figure 2.3).51  
 
Figure 2.3. HDAC Fluorescent activity assay. Deacetylation of the substrate sensitizes to the 
developer. 
 
To measure global HDAC inhibition, HeLa lysates, which contains a 
mixture of HDAC1-8 and HDAC10-11, were incubated with or without SAHA 
 
HDAC 
  
Developer (trypsin) 
 
Substrate 
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analogues in HDAC assay buffer solution.  After the initial incubation, Fluor de 
Lys® substrate in HDAC assay buffer was added to the reaction. The peptidic 
substrates consisted of an ε-acetylated lysine residue and a 4-methylcoumarin-7-
amide at the carboxy terminal unit. In the reaction catalyzed by HDACs, the 
acetylated lysine residue of the substrate was deacetylated, while acetylated 
lysine would remain in the reaction when inhibited by the SAHA analogues. To 
quench the reaction and allow color development, Fluor de Lys® developer was 
added to the reaction mixture. In this reaction, the only deacetylated peptidic 
lysine substrates containing the methylcoumarinamide were cleaved by trypsin to 
release the fluorescence molecule, methylcoumarin. In other word, the acetylated 
lysine substrate present when the reaction was inhibited by the SAHA analogues 
did not result in measurable cleavage by trypsin and did not release the 
fluorescence molecule (no fluorescence activity). As a result, the high level of 
deacetylated activity of the substrates indicated low inhibitory activity of the 
SAHA analogues. The fluorescence intensity was determined using a Geniosplus 
Fluorimeter (Tecan) with excitation at 360 nm and emission at 465 nm.  
 
2.6.2 HDAC assay procedure 
HDAC activity of the C3-SAHA analogues was measured using the Fluor 
de Lys™ activity assay (Biomol) using the manufacturer’s protocol by Dr. Sujith 
Weerasinghe. To measure global HDAC inhibition, HeLa lysates (approximately 
4µg of total protein) were incubated with small molecule inhibitor or without small 
molecule inhibitor (2% DMSO) in HDAC assay buffer (50 mM Tris/Cl, pH 8.0, 137 
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mM NaCl, 2.7 mM KCl, 1 mM MgCl2) at a final volume of 25 µL for 30 min at 30 
˚C with shaking.  Concentrations of small molecule between 1 nM and 1 mM 
final concentration were used to determine IC50 values.  Because the small 
molecules were stored in DMSO, dilution with HDAC buffer ensured that a 
maximum of 2% DMSO was present in the final reaction mixture.  After the initial 
incubation, Fluor de Lys™ substrate in HDAC assay buffer (100 µM final 
concentration) was added to make a total reaction volume of 50µL. The reaction 
mixture was incubated at 30˚C for 45 min with shaking. To quench the reaction 
and allow color development, Fluor de Lys™ developer (2.5 µL of 20X diluted up 
to  50 µL in HDAC assay buffer ) was added to give a final 100 µL volume and 
incubated with shaking for 5 min at room temperature. The fluorescence intensity 
was determined using a Geniosplus Fluorimeter (Tecan) with excitation at 360 
nm and emission at 465 nm.  
To perform the isoform selectivity studies, the procedure was similar 
except that the HeLa cell lysates were replaced with 0.2 µg HDAC1 (specific 
activity = 42.5 pmol/min/µg), 0.05 µg HDAC3 (specific activity = 249 pmol/min/µg) 
or 0.25 µg HDAC6 (specific activity = 257 pmol/min/µg), purchased from BPS 
Biosciences.  In addition, the Fluor de Lys™ substrate was used at a final 
concentration of 50 µM for HDAC1 or 25µM for HDAC3 and HDAC6. 
For each trial, a no enzyme control sample was used to assess the 
background. The background-corrected fluorescence units of small molecule-
treated samples were then compared to that of untreated samples (set to 100%) 
to give a percentage deacetylase activity. IC50 values were obtained by plotting 
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the percentage deacetylase activity versus the small molecule concentration and 
fitting the data to a sigmoidal dose-response curve (y=100/(1+(x/m3)m4) using 
KaleidaGraph software where m1 is the IC50 value in Molar units.  All 
experiments were performed in triplicate with the mean and standard error 
reported in the tables and figures.  
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CHAPTER 3 – SYNTHESIS OF SAHA ANALOGUES MODIFIED AT THE C6 
POSITION 
3.1 Rationale for design of SAHA analogues modified at the C6 position 
A limited number of structure activity relationship (SAR) studies on the 
linker area of SAHA have been performed, even though the linker region might 
influence inhibitory activity and selectivity (Section 1.7). In fact, many number of 
inhibitors that have substituents on the linker have been discovered with great 
potency and selective inhibition when substituents were attached near or on the 
capping group (Section 1.9). Specifically, tubacin with a bulky substituent at the 
capping group has been used in pharmacokinetic and clinical studies (Figure 
1.9). Also, based on data from previous C2 and C3-SAHA libraries26, 47, 
substituents on the C6 position might lead to potent inhibitory activities because 
C6-SAHA substituents would be located close to the solvent-exposed region of 
the active site. As discussed in the chapter 2, the C3-SAHA ethyl analogue 
showed selective inhibition for HDAC6 over HDAC1 and HDAC3.47 To expand 
our understanding of the impact of substituents, synthesis of C6-SAHA 
analogues with hydrophobic substituents was achieved because the carbon 
linker is surrounded by a hydrophobic tunnel. 
The earlier results from the C2 and 
C3-SAHA libraries showed that the steric 
environment on the SAHA carbon linker 
caused reduced inhibitory activity, in 
 
Figure 3.1. Structure of SAHA analogues 
containing substituents on the C6 position 
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addition to influencing selective inhibition.26, 52 With the potential to improve 
selectivity, the C6-SAHA library (Figure 3.1) was synthesized. We proposed that 
the HDAC protein active site would not only be more tolerant of bulkier 
substituents on the C6 position near the solvent-exposed area but the C6-SAHA 
analogues would also display more selectivity compared to the C2 and C3-SAHA 
analogues based on the previous reports about several class-selective inhibitors 
with bulky substituents in the capping group region (Section 1.9).20 
3.2 Initial synthesis 
To elucidate the impact of substituents present near the solvent-exposed 
area, C6-SAHA analogues were synthesized. Like C2 and C3-SAHA analogues 
(Chapter 1 and 2), we selected hydrophobic substituents since the carbon linker 
is surrounded by a hydrophobic tunnel (Figure 1.4). Also, we theorized that bulky 
analogues on the C6 position would display more potent inhibition compared to 
C2 and C3-SAHA analogues due to their proximity to the solvent-exposed 
surface. 
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Scheme 3.1. Initial synthesis of C6-SAHA analogue (methyl derivative 14a) 
Initially, we synthesized the C6-SAHA methyl analogue 14a, as outlined in 
Scheme 3.1. Due to symmetry compared to the C3-SAHA analogues, synthesis 
of the C6-SAHA analogues was straightforward and similar to that of the C3-
SAHA library. The major differences between two syntheses are the following. 
Commercially available ε-caprolactone 2 was opened to give methyl 6-
hydrohexanoate 9 under Fisher conditions instead of building the anilide 
derivative. The alcohol compound 9 was subjected to Swern oxidation to give 
aldehyde 10 similar to the C3-aldehyde formation. For the Horner-Wadsworth-
Emmons reaction, using benzyl dimethyl phosphonoacetate instead of using 
trimethyl phosphonoacetate gave the corresponding α,β-unsturated benzyl ester 
11 that allowed incorporation of substituents, which provided the precursor for 
anilide derivative 13a. A mixture of (E) and (Z)-isomers of ester 11 were treated 
with a copper (I) iodide to give the methyl substituted ester 12a. Similar to the 
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previous optimized synthesis of the C3-methyl SAHA analogue (Scheme 2) 
where the 1,4-addition demonstrated quantitative yield, the C6-methyl ester 12a 
was synthesized and characterized without impurities according to thin layer 
chromatography (TLC) and 1H & 13C NMR spectra analysis. Therefore, the 
methyl ester 12a without purification was deprotected by hydrogenolysis and 
coupled with aniline in 53% yield (over the three steps). In contrast to the C3-
SAHA library where the anilide derivative was installed at the beginning stage, 
the anilide 13a was created from benzyl ester 12a at a late stage, which attached 
substituents near the capping group. The methyl ester derivative 13a was directly 
converted to the methyl hydroxamic acid 14a. 
3.3 Modified synthesis 
 Scheme 3.2. Modified synthesis of C6-SAHA analogue 14b - 14d 
To create the remaining C6-SAHA analogues, first, purification by column 
chromatography was required after 1,4-addition since the mixture of (E) and (Z) 
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isomers 11 were unable to completely react to produce phenyl ester 12b, as was 
observed with the methyl derivative 12a (Scheme 3.2). Using the additional 
purification step after the 1,4-addition, the t-butyl ester 12c, 2-ethylhexyl ester 
12d, and isopropyl ester 12e were synthesized. The rest of syntheses for 
hydrogenolysis, coupling, and conversion to hydroxamic acid were similar to the 
methyl analogue synthesis. However, despite the purification, there was still 
remaining unsaturated ester 11 after 1, 4-addition for obtaining phenyl ester 12b 
due to the similar polarity. The mixture of unsaturated ester 11 and phenyl ester 
12b were subjected to hydrogenolysis and coupling to give anilide 13b and 
unsaturated anilide compound 13b´. Fortunately, 14b was completely purified 
after conversion to hydroxamic acid in 60% yield (over the four steps). 
3.4 Biological analysis 
The HDAC inhibitory activities of the C6-SAHA library were measured 
using the Fluor de Lys® in vitro fluorescence activity assay kit (Enzo). Unlike the 
C3-SAHA library, the C6-SAHA analogue biological activities were performed by 
Sun Ea Choi.  The activities of the C6-SAHA compounds are summarized in 
Table 3.1. Interestingly, the planar phenyl variant 14b was the most potent 
analogue displaying an IC50 of 344 nM similar to the C3-methyl variant 1e (IC50 of 
350 nM) and comparable to SAHA (4-fold reduced), IC50 of 86 nM. This is in 
contrast to the C3-phenyl variant 1b (IC50 of 73000 nM), which displayed 811-fold 
reduced activity versus SAHA.53 In addition, the smallest C6-methyl variant 14a 
(IC50 of 349 nM) displayed similar potency to the phenyl variant. These results 
indicate that the active site of HDAC proteins can accommodate a bulky 
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substituent at the C6 position. Moreover, the longest analogues, the 2-ethylhexyl 
variant 14d, still displayed potent inhibitory activity in the nM range. Likewise, the 
bulkiest substituent with three methyl groups at the α-carbon, the t-butyl variant 
14c, displayed only 20-fold reduced activity versus SAHA. In summary, the 
inhibition data show that most C6-SAHA analogues maintain nM potency, but 
substitution at the α-carbon decreases potent inhibitory activity. 
 
Table 3.1. HDAC inhibition by SAHA, MS-275, and the C6-SAHA analogues using HeLa 
cell lysates 
Compounds R IC50, nMª 
SAHA  86  4 
MS-275  3200  100 
14a Methyl 349  20 
14b Phenyl 344  40 
14c t-Butyl 1940  300 
14d 2-Ethylhexyl 456  30 
ªValues are the mean of at least three experiments with standard error given. 
 
These results are consistent with the hypothesis that the active site of 
HDAC proteins accommodates large substituents near the solvent exposed area. 
As expected, one trend for the C6-SAHA analogues is that the increasing size of 
substituents has less influence on inhibitory activity compared to the C2 and C3-
SAHA analogues.  
As mentioned earlier, the presence of methyl groups at the α-carbon 
decreased inhibitory activity. We speculate that the t-butyl variant 14c might 
display specific selectivity since the C3-ethyl variant 1c, which contains an α-
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methyl group, displayed selective inhibition for HDAC6 over HDAC1 and HDAC 3 
and also showed significantly decreased inhibitory activity compared with the C3-
methyl variant 1e. To explore the role of an α-methyl group on selectivity, 
synthesis of the isopropyl derivative would reveal the effect of α-carbon 
substituents. Another possibility is that the hybridization at the α-carbon might 
influence selectivity. For example, the C6-SAHA phenyl 14b and methyl variant 
14a have sp2 and sp3 orbital structures. The data might provide key structural 
information for binding site recognition. The long chain of the C6-SAHA 2-ethyl 
hexyl analogue 14d might also affect isoform selectivity. To verify the influence of 
sterics on isoform selectivity, testing the isoform selectivity of C6-SAHA 
analogues is described. The results of the isoform selectivity of the C6-SAHA 
analogues are outlined in Figure 3.2.  
The isoform selectivity of C6-SAHA analogues was tested with HDAC1 
and HDAC3 representing class I and HDAC6 representing class II. To assess the 
isoform selectivity, all compounds were tested at a single concentration near to 
their IC50 values using the Fluor de Lys® kit (Figure 3.2). As observed from 
previous data, SAHA exhibited roughly equal inhibition against HDAC1, HDAC3, 
and HDAC6. The phenyl variant 14b, which displayed the most potent inhibition 
among the C6-SAHA analogues with HeLa cell lysates, similarly inhibited 
HDAC1, HDAC3, and HDAC6 as well. In contrast, the methyl variant 14a showed 
dual-preference for HDAC1 and HDAC3 over HDAC6 at 500 nM even though the 
methyl 14a (IC50 of 349 nM) and phenyl variant 14b (IC50 of 344 nM) displayed 
equal inhibition in the HeLa cell lysates. The difference between sp3 and sp2 
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orbital structures might affect selectivity but not potency. The 2-ethylhexyl variant 
14d with an additional carbon chain displayed selectivity for HDAC3 over HDAC1 
and HDAC6 compared to the methyl variant 14a. Similar to the methyl variant 
14a (IC50 of 349 nM), the 2-ethylhexyl variant 14d (IC50 of 456 nM) imparted 
selectivity but not potency. However, the bulkiest analogue at the α–carbon 
position, t-butyl variant 14c, displayed the opposite selectivity with preference for 
HDAC1 and HDAC6 over HDAC3. In this case, the α-carbon substituent lead to 
different interactions with each isoform HDAC active sites. The t-butyl substituent 
encouraged dual-selectivity toward HDAC1 and HDAC6 over HDAC3, while the 
inhibitory activity of t-butyl variant 14c (IC50 of 1.9 µM) showed 5-fold reduced 
activity compared to the 2-ethylhexyl variant 14d (IC50 of 456 nM) and 20-fold 
less potent than SAHA (IC50 of 86 nM). In summary, the data indicated that the 
methyl, t-butyl, and 2-ethylhexyl variants (14a, 14c, and 14d) showed dissimilar 
preference for each isoform HDAC proteins despite parallel potency. The 
deacetylase activity of individual trial is summarized in Table C.5 in Appendix C.  
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 Figure 3.2. Initial screen of isoform selectivity of C6-SAHA analogues against 
 HDAC1, HDAC3, and HDAC6 with 125 nM SAHA, 500 nM 14a, b, d, and 2 µM 14c. 
 
To more thoroughly assess the selectivity observed in the initial screen, 
we determined the HDAC1, HDAC3, and HDAC6 IC50 values of the C6-t-butyl 
variant 14c because it showed the most potential to create a dual-selective 
inhibitor.  The C6-t-butyl analogue 14c displayed 6-fold greater potency for 
HDAC1 over HDAC3 and 2-fold greater potency for HDAC6 over HDAC3 (Table 
3.2). In addition, it displayed selectivity within class I for HDAC1 over HDAC3. As 
a control, SAHA displayed non-selective inhibitor activity against the isoform, as 
expected (Table 3.2).30 The selectivity analysis shows that a substituent on the 
C6 position can influence the selectivity of SAHA from non-selective inhibitor to a 
dual-selective HDAC1 and HDAC6 inhibitor. Furthermore, the C6-SAHA t-butyl 
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analogue displays an IC50 value of 1.9 µM in the lowmicromolar range, while the 
C3-SAHA ethyl analogue (HDAC6-selective inhibitor) displayed 16-fold 
decreasing potency (IC50 of 32 µM).
47 Therefore, the data indicate that attaching 
the t-butyl substituent to the linker chain on the C6 position may promote dual-
selective inhibition as well as potency on SAHA. 
 
Table 3.2. IC50 values of SAHA and the C6-SAHA t-butyl variant 14c 
for HDAC1, HDAC3, and HDAC6  
Compound IC50/µM 
HDAC1 HDAC3 HDAC6 
SAHA 0.096 ± 0.016 0.136 ± 11 0.074 ± 0.009 
14c 0.993 ± 0.061 5.4 ± 0.7 2.4 ± 0.5 
 
Specific selective HDAC inhibitors support pathological cardiac 
remodeling studies. For example, a recent cardiac study reported that stressed 
myocardium increased the catalytic activity of the class IIb HDAC, HDAC6.35 
Moreover, the best anti-leukemic activities in the four pediatric AML cell lines 
were observed by dual HDAC1 and HDAC6 inhibitors that inhibited both.45e . The 
function or regulation of dual-selective HDAC inhibitors is not well informed in 
present even though dual-selective HDAC inhibitors might guide development of 
prospective drugs of anti-diverse diseases.  
From the initial isoform selectivity screen (Figure 3.2), SAHA analogues 
with substituents on the C6 position displayed diverse selective inhibitions, such 
as class I selectivity (methyl 14a), dual-class I, II selectivity (t-butyl 14c), and 
isoform selectivity for HDAC3 (2-ethylhexyl 14d). Our results reveal that small 
59 
structural changes in the C6 position linker region of SAHA can significantly 
influence selectivity with suitable potency. 
3.5 Experimental 
3.5.1 General methods 
Additional details were shown in Section 2.5.1 of Chapter 2. 
3.5.2 Experimental Procedures and Compound Characterization  
 
 
Methyl 6-hydroxyhexanoate (9). Concentrated aqueous sulfuric acid (adjusted 
to pH 6 using neutral pH meter paper (pH 1 to pH 14 range) as assessed with) 
was dropwise added to a solution of ε–caprolactone (5.54 mL, 50 mmol) in 
MeOH (50 mL). The mixture was stirred for 20 min. The mixture was 
subsequently diluted with anhydrous diethyl ether (25 mL) and washed with 
distilled water (equal volume to organic layer). The aqueous layer was extracted 
with diethyl ether (equal volume to organic layer) at least 3 times. The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. 
The residue was purified by column chromatography (12% acetone/CH2Cl2) on 
silica gel to give 9 (7.23 g, 99%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.30 (m, 
2H), 1.50 (m, 2H), 1.56 (m, 2H), 2.24 (m, 2H), 2.59 (bs, 1H), 3.52 (m, 2H), 3.58 
(s, 3H); 13C-NMR (δ, ppm, CHLOROFORM-D): 24.8, 25.5, 32.4, 34.1, 51.8, 62.5, 
174.5; IR: 3424, 2940, 2866, 1738, 1438, 1205, 857, 744 cm-1; HRMS ( EI-TOF, 
m/z): found [M+Na] 169.0840, calc. for C7H14O3, 169.0841. 
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1-Benzyl 8-methyl oct-2-enedioate (11). To a solution of DMSO (1.02 mL, 
14.39 mmol) in CH2Cl2 (44 mL) was added 2 M oxalyl chloride in 
dichloromethane (3.27 mL, 6.54 mmol) dropwise and then methyl 6-
hydroxyhexanoate 9 (0.638 g, 4.36 mmol) stepwise at -78ºC. The reaction 
mixture was stirred for 45 min before triethylamine (TEA, 4.12 mL, 29.66 mmol) 
was added dropwise at -78 ºC. The mixture was warmed 
to room temperature and stirred for an additional 1 h. The 
reaction mixture was quenched by adding distilled water 
(44 mL). The mixture was washed with 1.0 M aqueous hydrochloric acid (44 mL), 
an aqueous solution of saturated NaHCO3 (44 mL), and brine (44 mL). The 
organic layer 10 was dried over anhydrous Na2SO4, filtered, and concentrated. 
 To a solution of NaH (0.513 g, 12.8 mmol) in THF (85 mL) was added 
benzyl dimethyl phosphonoacetate (3.31 g, 12.8 mmol) dropwise at 0 ºC and the 
mixture was stirred for 15 min. To the solution was added crude methyl 6-
oxohexanoate 10 (1.23 g, 8.55 mmol) at -78 ºC and the mixture was stirred for 15 
min. The mixture was allowed to warm to room temperature and stirred for an 
additional 1 h. The mixture was quenched by addition of an aqueous solution of 
saturated NH4Cl until evolution of gas was not observed. The mixture was 
washed with distilled H2O (85 mL). The organic layer was collected and the 
aqueous layer was extracted with diethyl ether (equal volume to aqueous layer) 
at least 3 times.  The combined organic layers were dried over anhydrous 
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Na2SO4, filtered, and concentrated. The residue was purified by column 
chromatography (diethyl ether: petroleum ether 1:6) on silica gel to give 11 (2.17 
g, 92%).  (E+Z)-isomer 1H-NMR (δ, ppm, CHLOROFORM-D): 1.48 (m, 2H), 
1.63 (m, 2H), 2.20 (q, 2H), 2.30 (t, 2H), 3.64 (s, 3H), 5.16 (s, 2H), 5.84 (d, 1H, 
J=180 Hz), 6.98 (m, 1H), 7.35 (m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 
24.6, 27.6, 32.1, 33.9, 51.7, 66.2, 121.6, 128.3, 128.4, 128.8, 136.3, 149.5, 
166.6, 174.0; IR: 3671, 2974, 1735, 1455, 1258, 1066, 907, 748, 698 cm-1; 
HRMS (EI-TOF, m/z): found [M+Na] 299.1269, calc. for C16H20O4Na, 299.1259. 
 
 
1-Benzyl 8-methyl 3-methyloctanedioate (12a). To a solution of Cu(I)I (1.06 g, 
5.57 mmol) in THF (19 mL) was added 1.6M methyllithium in diethyl ether (6.97 
mL, 11.15 mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The 
reaction mixture was cooled to -78 ºC before addition of trimethylsilyl chloride 
(TMSCl, 4.25 mL, 33.48 mmol). To the reaction mixture was dropwise added 1-
benzyl 8-methyl oct-2-enedioate 11 (513 mg, 1.86 mmol) at -78 ºC. The reaction 
was stirred for 3 h at -78 ºC to room temperature and then quenched by addition 
of 1.0 M aqueous hydrochloric acid until a color of the mixture changed to blue 
(CuCl2(aq)). The organic layer was collected and the aqueous layer was extracted 
with diethyl ether (equal volume to aqueous layer) at least 3 times. The combined 
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated. 
1H-
NMR (δ, ppm, CHLOROFORM-D): 0.91 (d, 3H), 1.30 (m, 4H), 1.58 (m, 2H), 1.96 
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(m, 1H), 2.19 (q, 1H), 2.32 (m, 3H), 3.65 (s, 3H), 5.10 (s, 2H), 7.34 (m, 5H); 13C-
NMR (δ, ppm, CHLOROFORM-D): 19.9, 25.2, 26.6, 30.4, 34.2, 36.4, 42.0, 51.7, 
66.3, 128.4, 128.5, 128.8, 136.3, 173.2, 174.4; HRMS (EI-TOF, m/z): found 
[M+Na] 315.1569, calc. for C17H24O4Na, 315.1572. 
 
 
 
1-Benzyl 8-methyl 3-phenyloctanedioate (12b). To a solution of Cu(I)I (827 
mg, 4.34 mmol) in THF (14.5 mL) was added phenyl lithium 2.0M (4.34 mL, 8.69 
mmol) dropwise at -15 ºC and the mixture was stirred for 20 min. The reaction 
mixture was cooled to -78 ºC. To the solution was added trimethylsilyl chloride 
(TMSCl, 1.67 mL, 13.03 mmol) dropwise and then 1-benzyl 8-methyl oct-2-
enedioate 11 (400 mg, 1.45 mmol) stepwise at -78 ºC.  The mixture was stirred 
for 3 h at -78 ºC and then quenched by addition of an aqueous solution of 
saturated NH4Cl: saturated NH4OH (1:1) until the color of the mixture turned to 
blue ((NH3)4CuCl2(aq)). The mixture was washed with the aqueous solution of 
saturated NH4Cl: NH4OH (1:1) (14.5 mL). The organic layer was collected and 
the aqueous layer was extracted with diethyl ether (equal volume to the aqueous 
layer). The combined organic layers were dried over anhydrous Na2SO4, filtered, 
and concentrated. The residue was purified by column chromatography (diethyl 
ether: petroleum ether 1:6) on silica gel to give 12b + 11 (3:1).   
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1-Benzyl 8-methyl 3-(tert-butyl)octanedioate (12c). The synthesis was similar 
that of 12b except the following reagents were used: Cu(I)I (827 mg, 4.34 mmol) 
in THF (10.9 mL), tert-butyllithium 1.6M (5.43 mL, 8.69 mmol), TMSCl (1.67 mL, 
13.03 mmol), and 1-benzyl 8-methyl oct-2-enedioate 11 (300 mg, 1.09 mmol).  
The product was purified by column chromatography (diethyl ether: petroleum 
ether 1:6) on silica gel to give 12c (313 mg, 89%). 1H-NMR (δ, ppm, 
CHLOROFORM-D): 0.84 (s, 9H), 1.05 (m, 1H), 1.17-1.35 (m, 2H), 1.47-1.62 (m, 
3H), 1.68 (m, 1H), 2.10 (q, 1H), 2.23 (t, 2H), 2.41 (q, 1H), 3.64 (s, 3H), 5.09 (s, 
2H), 7.34 (m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 25.5, 27.6, 28.5, 31.0, 
33.8, 34.2, 36.3, 45.2, 51.6, 66.4, 128.4, 128.6, 128.7, 136.3, 174.3, 174.5; IR: 
2952, 2869, 1737, 1457, 1367, 1151, 914, 737 cm-1. MS (ESI, m/z): found [M+ 
+Li] 341.28, calc. for C20H30O4Li, 341.23. 
 
1-Benzyl 8-methyl 3-(2-ethylhexyl)octanedioate (12d). The synthesis was 
similar to that of 12b except the following reagents were used: Cu(I)Br∙SMe2  
(1.89 g, 9.19 mmol) in THF (15.3 mL), 2-ethylhexyllithium (10.09 mL, 18.38 
mmol), TMSCl (3.52 mL, 27.57 mmol), and 1-benzyl 8-methyl oct-2-enedioate 11 
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(400 mg, 1.53 mmol). The product was purified by column chromatography 
(diethyl ether: petroleum ether 1:8) on silica gel to give 12d (485 mg, 81%). 1H-
NMR (δ, ppm, CHLOROFORM-D): 0.79 (m, 3H), 0.88 (t, 3H), 1.23-1.31 (m, 
15H), 1.58 (m, 2H), 1.91 (m, 1H), 2.25-2.30 (m, 4H), 3.66 (s, 3H), 5.11 (s, 2H), 
7.35 (m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 10.7, 14.40, 23.4, 25.4, 
26.1, 28.9, 32.8, 33.1, 34.2, 36.1, 38.5, 44.4, 66.3, 128.4, 128.6, 128.8, 129.2, 
130.4, 173.2, 173.5; IR: 2956, 2858, 1739, 1457, 1167, 912, 741 cm-1. MS (ESI, 
m/z): found [M++K] 429.29, [M++Li] 397.36, [M++Na] 413.31, calc. for C24H38O4K, 
429.65, C24H38O4Li, 397.50, C24H38O4Na, 413.55. 
 
1-Benzyl 8-methyl 3-isopropyloctanedioate (12e). The synthesis was similar 
that of 12b except the following reagents were used: Cu(I)I (875 mg, 4.59 mmol) 
in THF (7.7 mL), isopropyl magnesium bromide 1.94M (2.37 mL, 4.59 mmol), 
TMSCl (1.76 mL, 13.78 mmol) and 1-benzyl 8-methyl oct-2-enedioate 11 (200 
mg, 0.77 mmol). The residue was purified by column chromatography (diethyl 
ether: petroleum ether 1:6) on silica gel to give 12e (109 mg, 45%). 1H-NMR (δ, 
ppm, CHLOROFORM-D): 0.80 (d, 3H), 0.84 (d, 3H), 1.16-1.33 (m, 4H), 1.59 (m, 
2H), 1.70 (m, 1H), 1.78 (m, 1H), 2.18 (m, 1H), 2.27 (m, 3H), 3.65 (s, 3H), 5.10 (s, 
2H), 7.35 (m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 18.4, 19.4, 25.1, 26.8, 
29.7, 30.7, 34.0, 36.0, 40.7, 51.5, 66.1, 128.2, 128.3, 128.5, 136.1, 173.9, 174.2; 
IR: 3033, 2954, 2873, 1737, 1458, 1332, 1261, 1008, 905, 750 cm-1; HRMS (EI-
TOF, m/z): found [M+Na] 343.1883, calc. for C19H28O4Na, 343.1885. 
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Methyl 6-methyl-8-oxo-8-(phenylamino)octanoate (13a). To a solution of 
crude 1-benzyl 8-methyl 3-methyloctanedioate 12a (513 mg, 1.86 mmol) in ethyl 
acetate (19 mL) was added 20% Pd(OH)2/C (261 mg, 0.372 mmol) and the 
reaction mixture was purged with H2 gas for 30 s. The reaction solution was 
stirred under H2 gas for 3 h and then filtered through a plug of Celite with ethyl 
acetate (57 mL). The filtrate was concentrated to give 8-methoxy-3-methyl-8-
oxooctanoic acid as clear oil.   The crude residue, 8-methoxy-3-methyl-8-
oxooctanoic acid, was transferred to a flask and dissolved in 19 mL of 
acetonitrile. TBTU (895 mg, 2.79 mmol), diisopropylethylamine (647 mL, 3.72 
mmol), and aniline (254 mL, 2.79 mmol) was added to the flask. The reaction 
mixture was stirred for 3 h. The mixture was then quenched with 19 mL of 
saturated NaHCO3 solution, transferred to a separatory funnel and extracted with 
ethyl acetate (equal volume to aqueous layer) at least 3 times. The combined 
organic layers were dried over magnesium sulfate, filtered, and evaporated to oil. 
Flash silica gel chromatography (1:6 diethyl ether: petroleum ether → 1:1 diethyl 
ether: petroleum ether) afforded 274 mg of the anilide 13a as a clear oil (53% 
over 3 steps).   1H-NMR (δ, ppm, CHLOROFORM-D): 0.91 (d, 3H), 1.13-1.34 
(m, 4H), 1.56 (m, 2H), 2.09 (m, 2H), 2.27 (m, 3H), 3.61 (s, 3H), 7.02 (t, 1H), 7.24 
(t, 2H), 7.52 (d, 2H), 8.27 (bs, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D):  19.9, 
25.1, 26.6, 30.9, 34.2, 36.5, 45.6, 51.8, 120.0, 124.4, 129.2, 138.2, 171.1, 175.3; 
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IR: 3306, 2952, 2868, 1739, 1601, 1544, 1151, 913, 757 cm-1; HRMS (EI-TOF, 
m/z): found [M+H] 278.1764, calc. for C16H24NO3, 278.1756, found [M+Na] 
300.1584, calc. for C16H24NO3Na, 300.1576. 
 
Methyl 6-(tert-butyl)-8-oxo-8-(phenylamino)octanoate (13c). A similar 
procedure to that for 13a was used, except for the following reagents: 20% 
Pd(OH)2/C (210 mg, 0.299 mmol) and 1-benzyl 8-methyl 3-(tert-
butyl)octanedioate 12c (414 mg, 0.748 mmol) in ethyl acetate (7.5 mL), TBTU 
(360 mg, 1.121 mmol) in acetonitrile (7.5 mL), diisopropyethylamine (521 mL, 
2.99 mmol), aniline (102 mL, 0.748 mmol) and stirring for 4 h. The mixture was 
then quenched with 7.5 mL of saturated NaHCO3 solution, transferred to a 
separatory funnel and extracted with ethyl acetate (equal volume to aqueous 
layer) at least 3 times. The organic layer was dried over magnesium sulfate, 
filtered, and evaporated to oil. In this case, flash silica gel chromatography (1:6 
diethyl ether: petroleum ether → 1:1 diethyl ether: petroleum ether) afforded 185 
mg of the anilide 13c as a clear oil (58% over 2 steps). 1H-NMR (δ, ppm, 
CHLOROFORM-D): 0.91 (s, 9H), 1.13 (m, 1H), 1.33 (m, 1H), 1.42 (m, 1H), 1.55 
(m, 3H), 1.82 (m, 1H), 2.09 (q, 1H), 2.28 (t, 2H), 2.49 (q, 1H), 3.62 (s, 3H), 7.09 
(t, 1H), 7.21 (bs, 1H), 7.31 (t, 2H), 7.50 (d, 2H); 13C-NMR (δ, ppm, 
CHLOROFORM-D):  25.5, 27.8, 28.4, 31.2, 34.0, 34.1, 45.1, 56.1, 62.8, 119.2, 
124.3, 129.2, 134.7, 168.5, 171.3; IR: 3055, 2952, 2865, 1732, 1600, 1265, 741, 
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706 cm-1; HRMS (EI-TOF, m/z): found [M+H] 320.2229, calc. for C19H29NO3, 
320.2226, found [M+Na] 342.2048, calc. for C19H29NO3Na, 342.2045. 
 
 
Methyl 8-ethyl-6-(2-oxo-2-(phenylamino)ethyl)dodecanoate (13d). A similar 
procedure to that for 13a was used, except for the following reagents: 20% 
Pd(OH)2/C (345 mg, 0.492 mmol) and 1-benzyl 8-methyl 3-(2-
ethylhexyl)octanedioate 12d (463 mg, 1.229 mmol) in ethyl acetate (12.3 mL), 
TBTU (592 mg, 1.844 mmol) in acetonitrile (12.3 mL), diisopropyethylamine (856 
mL, 4.916 mmol), aniline (168 mL, 1.844 mmol) and stirring for 3 h. In this case, 
the mixture was quenched with 12.3 mL of saturated NaHCO3 solution, 
transferred to a separatory funnel and extracted with CH2Cl2 (equal volume to 
aqueous layer) at least 3 times. The organic layer was dried over magnesium 
sulfate, filtered, and evaporated to oil. The product was purified by column 
chromatography (diethyl ether: petroleum ether 1:8) on silica gel to give 13d (349 
mg, 76%).  1H-NMR (δ, ppm, CHLOROFORM-D): 0.81-0.87 (m, 6H),1.10-1.34 
(m, 15H), 1.60 (m, 2H), 2.03 (m, 1H), 2.22-2.32 (m, 4H), 3.65 (s, 3H), 7.08 (t, 
1H), 7.32 (t, 2H), 7.51 (d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-D):  10.7, 
14.4, 23.4, 25.3, 25.8, 26.0, 28.9, 33.1, 33.2, 33.6, 33.8, 36.2, 38.5, 43.2, 51.7, 
120.0, 124.3, 129.2, 138.3, 171.4, 174.6; IR: 3322, 3066, 2956, 1740, 1661, 
68 
1171, 912, 746, 694 cm-1; MS (ESI, m/z): found [M++Li] 382.41, [M++Na] 398.35, 
[M++K] 414.31, calc. for C23H37NO3Li, 382.49, C23H37NO3Na, 398.53, 
C23H37NO3K, 414.64. 
 
 
Methyl 6-isopropyl-8-oxo-8-(phenylamino)octanoate (13e). A similar 
procedure to that for 13a was used, except for the following reagents: 20% 
Pd(OH)2/C (88 mg, 0.125 mmol) and 1-benzyl 8-methyl 3-isopropyloctanedioate 
12e (0.312 mmol) in ethyl acetate (3 mL), TBTU (150 mg, 0.468 mmol) in 
acetonitrile (3 mL), diisopropyethylamine (218 mL, 1.248 mmol), aniline (43 mL, 
0.468 mmol) and stirring for 3 h. In this case, the product was purified by column 
chromatography (1:6 diethyl ether: petroleum ether → 1:1 diethyl ether: 
petroleum ether) on silica gel to give 13e (71 mg, 75%). 1H-NMR (δ, ppm, 
CHLOROFORM-D): 0.84 (d, 3H), 0.89 (d, 3H), 1.25-1.38 (m, 4H), 1.61 (m, 2H), 
1.81 (m, 1H), 1.90 (m, 1H), 2.15 (q, 1H),  2.30 (t, 2H), 2.34 (q, 1H), 3.64 (s, 3H), 
7.09 (t, 1H), 7.31 (t, 2H), 7.41 (bs, 1H), 7.51 (d, 2H); 13C-NMR (δ, ppm, 
CHLOROFORM-D):  18.9, 19.5, 25.3, 26.9, 29.7, 30.6, 34.1, 39.6, 41.1, 51.8, 
120.0, 124.4, 129.2, 138.3, 171.8, 174.6; IR: 3297, 3140, 2954, 2870, 1739, 
1601, 1368, 906, 757, 693 cm-1; HRMS (EI-TOF, m/z): found [M+H] 306.2071, 
calc. for C18H28NO3, 306.2069, found [M+Na] 328.1884, calc. for C18H28NO3Na, 
328.1889. 
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N8-Hydroxyl-3-methyl-N1-phenyloctanediamide (14a). To a solution of 
NH2OH∙HCl (677 mg, 9.735 mmol) in methanol (10 mL) was added KOH (1.092 
g, 19.469 mmol) at 0 ˚C in an acid-washed 25mL round-bottom flask.  After 
stirring for 20 min, methyl 6-methyl-8-oxo-8-(phenylamino)octanoate 13a (270 
mg, 0.974 mmol) was added and the mixture was stirred for 8 h at 0°C. The 
reaction mixture was adjusting to pH 6 by adding concentrated aqueous 
hydrochloric acid. The mixture was diluted with 30 mL of ethyl acetate, and 
washed with 30 mL of distilled water. The organic layer was dried over 
anhydrous Na2SO4, filtered, and concentrated. The residue was purified by 
column chromatography (9% methanol/CH2Cl2) on acid-washed silica gel to give 
14a (159 mg, 58%) as a clear oil.   1H-NMR (δ, ppm, METHANOL-D4): 0.98 (d, 
3H), 1.24-1.44 (m, 4H), 1.61 (m, 2H), 2.02 (m, 1H), 2.09 (t, 2H), 2.16 (q, 1H), 
2.34 (q, 1H), 7.07 (t, 1H), 7.29 (t, 2H), 7.52 (d, 2H); 13C-NMR (δ, ppm, 
METHANOL-D4):  18.7, 25.7, 26.3, 30.8, 32.5, 36.3, 44.4, 120.2, 124.0, 128.6, 
138.6, 171.8, 172.9; IR: 3270, 2928, 2868, 1643, 1600, 1500, 1418, 1116, 977, 
759, 693 cm-1; HRMS (EI-TOF, m/z): found [M+H] 279.1710, calc. for 
C15H23N2O3, 279.1709, found [M+Na] 301.1531, calc. for C15H23N2O3Na, 
301.1528. 
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N8-Hydroxyl-N8, 3-diphenyloctanediamide (14b). The synthesis of methyl 6-
phenyl-8-oxo-8-(phenylamino)octanoate 13b was similar to that of 14a except the 
following reagents were used: 20% Pd(OH)2/C (153 mg, 0.218 mmol) and 1-
benzyl 8-methyl 3-phenyloctanedioate 12b (0.546 mmol) in ethyl acetate (5.5 
mL), TBTU (263 mg, 0.818 mmol) in acetonitrile (5.5 mL), diisopropyethylamine 
(190 mL, 1.09 mmol), aniline (75 mL, 0.818 mmol) and stirring for 4 h. In this 
case, the reaction mixture was quenched with 5.5 mL of saturated NaHCO3 
solution, transferred to a separatory funnel and extracted with CH2Cl2 (equal 
volume to aqueous layer) at least 3 times. The organic layer was dried over 
magnesium sulfate, filtered, and evaporated to oil. Flash silica gel 
chromatography (diethyl ether: petroleum ether 1:1) afforded the mixture of 
phenyl substituted anilide 13b and α, β unsaturated anilide 13b´ as a clear oil.  
To a solution of NH2OH∙HCl (696 mg, 10.721 mmol) in methanol (10.7 mL) 
was added KOH (1.203 g, 21.442 mmol) at 0 ˚C in an acid-washed 25mL round-
bottom flask.  After stirring for 20 min, the mixture of methyl 6-phenyl-8-oxo-8-
(phenylamino)octanoate 13b and α, β unsaturated anilide 13b´ (1.072 mmol)   
was added and the reaction mixture was stirred for 8 h at 0°C. The rest of the 
reaction procedure was similar to that for 14a. The residue was purified by 
column chromatography (4% methanol/CH2Cl2) on acid-washed silica gel to give 
14b (221 mg, 60% over 4 steps).  1H NMR (δ, ppm, DIMETHYLSULFOXIDE-
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D6): 0.85-1.25 (m, 3H), 1.42 (m, 2H), 1.58 (m, 2H), 1.83 (t, bs, 2H), 2.57 (m, 2H), 
3.07 (m, 1H), 6.97 (t, 1H), 7.14-7.27 (m, 7H), 7.47 (d, 2H), 8.61 (s, 1H), 9.80 (s, 
1H), 10.25 (s, 1H); 13C-NMR (δ, ppm, METHANOL-D4):  25.5, 26.9, 32.5, 35.5, 
42.8, 44.5, 120.4, 124.1, 126.4, 127.5, 128.4, 128.5, 138.4, 144.1, 171.7, 171.9; 
IR: 3235, 3027, 2928, 2859, 1874, 1641, 1599, 1544, 1498, 1467, 1116, 977, 
757,699 cm-1; HRMS (EI-TOF, m/z): found [M+H] 341.1877, calc. for C20H25N2O3, 
341.1865, found [M+Na] 363.1697, calc. for C20H25N2O3Na, 363.1685. 
 
 
3-(tert-Butyl)-N8-hydroxyl-N1-phenyloctanediamide (14c). A similar procedure 
to that for 14a was used, except for the following reagents: NH2OH∙HCl (348 mg, 
5.008 mmol) in methanol (7.4 mL), KOH (562 mg, 10.018 mmol), methyl 6-(tert-
butyl)-8-oxo-8-(phenylamino)octanoate 13c (160 mg, 0.501 mmol) and stirring for 
4 h. In this case, the product was purified by column chromatography (4 % 
methanol/CH2Cl2) on acid-washed silica gel to give 14c (158 mg, 99%).  
1H-
NMR (δ, ppm, METHANOL-D4): 0.92 (s, 9H), 1.15 (m, 1H), 1.28 (m, 1H), 1.40 
(m, 1H), 1.58 (m, 3H), 1.77 (m, 1H), 2.04 (t, 2H), 2.16 (q, 1H), 2.53 (q, 1H), 7.07 
(t, 1H), 7.29 (t, 2H), 7.50 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4): 26.1, 26.7, 
28.6, 30.8, 32.6, 33.3, 38.5, 45.0, 120.2, 123.9, 128.6, 138.8, 171.8, 173.9; IR: 
3350, 2956, 2870, 1938, 1648, 1547, 1500, 1119, 976, 757, 693 cm-1; HRMS (EI-
TOF, m/z): found [M+H] 321.2180, calc. for C18H29N2O3, 321.2178, found [M+Na] 
343.1998, calc. for C18H29N2O3Na, 343.1988. 
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3-(2-Ethylhexyl)-N8-hydroxyl-N1-phenyloctanediamide (14d). A similar 
procedure to that for 14a was used, except for the following reagents: 
NH2OH∙HCl (629 mg, 9.054 mmol) in methanol (9 mL), KOH (1.016 g, 18.108 
mmol), methyl 8-ethyl-6-(2-oxo-2-(phenylamino)ethyl)dodecanoate 13d (340 mg, 
0.905 mmol), and stirring for 6 h. In this case, the product was purified by column 
chromatography (4 % methanol/CH2Cl2) on acid-washed silica gel to give 14d 
(199 mg, 58%).  1H-NMR (δ, ppm, METHANOL-D4): 0.85 (m, 6H), 1.19-1.37 (m, 
16H),1.61 (m, 2H), 2.02 (bs, 1H), 2.09 (t, 2H), 2.24 (m, 2H), 7.07 (t, 1H), 7.29 (t, 
2H), 7.53 (d, 2H); 13C-NMR (δ, ppm, METHANOL-D4):  9.7, 9.9, 13.4, 23.0, 
26.0, 28.5, 28.8, 32.6, 32.8, 33.0, 34.0, 36.1, 38.4, 42.3, 120.1, 124.0, 128.6, 
138.7, 171.8, 173.1; IR: 3391, 3256, 3065, 2956, 1643, 1600, 1539, 1500, 1308, 
903, 756, 692 cm-1; HRMS (EI-TOF, m/z): found [M+H] 377.2798, calc. for 
C22H37N2O3, 377.2804. 
 
3.5   HDAC assay procedure 
HDAC activity was measured using the Fluor de Lys® activity assay 
(Enzo) using the manufacturer’s protocol. To measure global HDAC inhibition, 
HeLa lysates (approximately 4µg of total protein) were incubated with small 
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molecule inhibitor or without small molecule inhibitor (2% DMSO) in HDAC assay 
buffer (50 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) in a final 
volume of 25 µL for 20 min at 23 ˚C with 600 rmp shaking.  Concentrations of 
small molecule between 1 nM and 1 mM were used to determine IC50 values 
(Appendix C. Table C.1-C.6).  Because the small molecules were stored in 
DMSO, dilution with HDAC buffer ensured that a maximum of 2% DMSO was 
present in the final reaction mixture.  After the initial incubation, Fluor de Lys® 
substrate in HDAC assay buffer (100 µM final concentration) was added to make 
a total reaction volume of 50µL. The reaction mixture was incubated at 30˚C for 
30 min with 600 rmp shaking. To quench the reaction and allow color 
development, Fluor de Lys® developer (2.5 µL of 20X diluted up to  50 µL in 
HDAC assay buffer ) was added to give a final 100 µL volume and incubated with 
shaking for 5 min at room temperature. The fluorescence intensity was 
determined using a Geniosplus Fluorimeter (Tecan) with excitation at 360 nm 
and emission at 465 nm.  
To perform the isoform selectivity studies, the procedure was similar 
except that the HeLa cell lysates were replaced with 0.2 µg HDAC1 (specific 
activity = 42.5 pmol/min/µg), 0.05 µg HDAC3 (specific activity = 249 pmol/min/µg) 
or 0.25 µg HDAC6 (specific activity = 257 pmol/min/µg), purchased from Enzo 
Life Sciences.  In addition, the Fluor de Lys® substrate was used at a final 
concentration of 50 µM for HDAC1 and HDAC6 or 25µM for HDAC3. 
For each trial, a no enzyme control sample was used to assess the 
background. The background-corrected fluorescence units of small molecule-
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treated samples were then compared to that of untreated samples (set to 100%) 
to give a percentage deacetylase activity. IC50 values were obtained by plotting 
the percentage deacetylase activity versus the small molecule concentration and 
fitting the data to a sigmoidal dose-response curve (y=100/(1+(x/m3)m4) using 
KaleidaGraph software where m1 is the IC50 value in Molar units.  All 
experiments were performed in triplicate with the mean and standard error 
reported in the tables and figures.  
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CHAPTER 4 – SYNTHESIS OF SAHA ANALOGUES MODIFIED AT THE C7 
POSITION 
4.1 Rationale for design of the SAHA analogues modified at the C7 
position  
SAHA analogues with substituents on C2 and C3 position displayed 
decreasing inhibitory activity while C6-SAHA analogues displayed similar 
potency to the parent compound, SAHA. These results indicate that only limited 
steric environment exists near hydroxamic acid. For example, the C6-SAHA 
analogue with the phenyl substituent displayed only 4-fold decreased inhibition 
while the C3-SAHA analogue with the phenyl substituent displayed more 800-fold 
decreased inhibitory activity compared to SAHA. Based on an analysis of the 
HDAC crystal structure (Figure 1.4)54, more space near the capping group area is 
available to accommodate bulky groups compared to the area near the 
hydroxamic acid. Moreover, large capping groups have been synthesized and 
displayed nM range inhibition.21b, 38 Several class-selective HDAC inhibitors have 
been synthesized that contain large groups in capping group region.20 Therefore,  
design, synthesis, and evaluation of a C7-SAHA library (Figure 4.1) are 
necessary to elucidate the structural requirement of HDAC inhibitors, since C7-
SAHA analogues are located closest to the solvent-exposed region through the 
linker area.  
 C7-SAHA analogues with 
hydrophobic substituents were generated. 
Synthesizing C7-SAHA analogues with 
 
Figure 4.1. Structure of SAHA analogues  
containing substituents on the C7 position 
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only hydrophobic substituents might be sub-optimal since the C7 position is 
between the hydrophobic tunnel and the solvent exposed area. Therefore, we 
synthesized the methyl pyridyl variant to study the influence of polar groups. In 
addition, since medicinal and natural compounds containing nitrogen were 
involved in diverse therapeutic areas (Chapter 1), we chose the pyridyl 
derivative.41-42, 55 Since hydrophobic substituents attached at the C6 position, a 
position that is close to the solvent-exposed location, displayed more potent 
inhibition compared to the C2 and C3-SAHA libraries, C7-SAHA analogues might 
also display potent inhibition compared to the C2, C3, and C6-SAHA analogues. 
Therefore, large aromatic groups should be incorporated on the C7 position. We 
designed a variety of substituents from the small methyl substituent to the large 
4-methylnaphthyl, methylbiphenyl, methylanthracene, and 
methyltetrahydroanthracene substituents to address what effect large groups 
impart on potency. Due to the structural similarity to the previously reported C2-
SAHA analogues, a straightforward synthetic approach was envisioned. 
 
4.2 Initial synthesis of C7-SAHA analogues  
Initially, C7-SAHA analogues with methyl 22a, benzyl 22b, and 4-
methylnaphthyl 22c substituents were synthesized by Dr. A. Bieliauskas. The 
early synthetic route for C7-SAHA analogues is outlined in Scheme 4.1. 
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Scheme 4.1. Initial synthesis of C7-SAHA analogues 22a-22c 
Benzyl ester 16 was obtained by coupling conditions with benzyl alcohol 
and 6-bromohexanoic acid 15. t-Butyl malonate derivatives 17 after nucleophilic 
substitution reaction provided the scaffold to create alkylated malonate 
derivatives 18a-c. In acidic conditions, the t-butyl groups in 18a-c were 
deprotected and decarboxylation was accomplished under reflux to give 
monocarboxylic acid 19a-c, which was coupled with aniline. The benzyl group in 
20a-c was removed by Pd/C, and was coupled with O-benzyl-protected 
hydroxamine. O-benzyl-protected hydroxamic acid 21a-c was deprotected by 
hydrogenolysis to give the C7- SAHA methyl, benzyl, and methylnaphthyl 22a-c.  
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HDAC inhibitory activities of the C7-methyl, benzyl, and 4-methylnaphthyl 
SAHA analogues 22a-c were measured using the Fluor de Lys™ in vitro 
fluorescence activity assay kit (Biomol) by Dr. S. V. W. Weerasinghe (Table 4.1). 
  
Table 4.1. HDAC inhibition by SAHA, C7-methyl, benzyl, and 4-naphthyl variants 
using HeLa cell lysates 
Compounds R IC50, nMª 
SAHA  86  4 
22a Methyl 105  6 
22b Benzyl 109  5 
22c 1-Naphthylmethyl 16  1 
ªValues are the mean of at least three experiments with standard error given. 
 
The C7-methyl and benzyl analogues 22a-b were equipotent in 100 nM 
range similar to SAHA (86 nM). The inhibition results are consistent with the 
hypothesis that greater steric tolerance exists in HDAC active site at the entrance 
area of capping group than the metal binding moiety region. Moreover, the 
largest compound, C7-SAHA naphthylmethyl analogue 22c among three 
analogues, displayed greater than 5-fold increasing inhibitory activity compared 
to SAHA. The addition of certain groups at the C7 position showed favourable 
interaction between the entrance area of HDAC active site and large bulky 
groups at the C7 position.  
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4.3 Synthesis of the C7-SAHA analogues with pyridyl and bulky 
substituents 
To thoroughly explore the impact of the large bulky groups at the C7 
position, additional large groups should be investigated. For example, the 4-
methylbiphenyl and 9-methylanthracene variants 22e-f should be synthesized to 
verify how large groups at the C7 position could interact with the HDAC active 
site. In addition, the inclusion of polar groups should be included to validate 
interaction between HDAC active site and hydrophilic substituents at the C7 
position, the end edge of the hydrophobic channel. However, the synthesis of 
C7-SAHA analogues containing bulkier and larger substituents than the methyl, 
benzyl, and 4-methylnaphthyl variants 22a-c faced issue in the nucleophilic 
substitution reaction (17->18) (Scheme 4.1). Therefore, the synthesis 
methodology was redesigned (Scheme 4.2). First of all, we used commercially 
available methyl 6-bromohexanoate 23 as the starting material instead of using 
coupling reaction to obtain benzylester 16 (two-step) (Scheme 4.1). Second, the 
nucleophilic substitution reaction was accomplished with dibenzylmalonate, 
which has a planar structure compared to the bulky t-butylmalonate (Scheme 
4.1) to give the dibenzylmalonate derivatives 24 (Scheme 4.2).  Finally, direct 
conversion to hydroxamic acid 22 was accomplished in one step without 
saponification, coupling O-benzyl hydroxylamine, and benzyl deprotection.47 The 
4-(1,1'-Biphenyl)methyl variant 22e was synthesized by Geetha Padige, the 9-
anthracenylmethyl 22f and 9-(1,2,3,4-tetrahydroanthracenyl)methyl 22g 
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derivatives  were synthesized by Satish Garre, and the 4-pyridylmethyl variant 
22d was synthesized under my responsibility. 
The alternative synthetic route of the C7-SAHA library had been designed 
by the main concern for bulky subsitutuent attachment when the nucleophilic 
substitution (24->25) reaction was performed with large groups. Additionally, 
several steps were improved in Scheme 4.2.  
 
Scheme 4.2. Redesigned synthesis of C7-SAHA library for bulky groups 
After successful nucleophilic substitution reaction with the 
dibenzylmalonate derivatives 24 and remaining substituents (pyridylmethyl, 
biphenylmethyl, and anthracenylmethyl groups), alkylated malonate derivatives 
25d-f were deprotected by Pd/C under hydrogen gas. Interestingly, the pyridyl 
and anthracenylmethyl groups were reduced when the dibenzyl groups of 
compounds 25d-f were deprotected. Zacharie and co-workers have proven the 
reduction from pyridine derivatives to piperidine derivatives in the mild 
condition.56 After deprotection by Pd/C, decarboxylation under the reflux 
condition, and coupling with aniline (three-step), there were additional anilide 
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products, the anthracenylmethyl anilide derivative 26f and the tetrahydro-
anthracenylmethyl anilide derivative 26g. In contrast, pyridyl and piperidylmethyl 
anilide derivatives 26d, 26d´ were unable to be isolated. The anthracenylmethyl 
and tetrahydroanthracenylmethyl anilide derivatives 26f, 26g were directly 
convert to hydroxamic acid 22f, 22g. 
4.4 Optimized synthesis for the C7-pyridyl analogue 
To synthesize the C7-pyridyl hydroxamic acid 22d, the synthetic method 
was redesigned since the pyridyl and piperidylmethyl anilide derivatives were not 
isolated (Scheme 4.3). The initial synthesis performed by Dr. Bieliauskas was 
modified since the pyridylmethyl group is smaller than naphthylmethyl group. 
However, several reaction conditions were improved. 
First of all, benzyl ester 16 was obtained under Fisher condition (95% 
yield) with benzyl alcohol and 6-bromohexanoic acid 15 instead of the coupling 
reaction (80% yield). The nucleophilic substitution reaction with t-butyl malonate 
generated derivative 17, which was alkylated with bromomethyl pyridine to 
produce alkylated malonate derivatives 18d. Compared to Dr. Bieliaskas’ 
synthesis, the alkylation was performed under the kinetic condition in DMF at 0 
ºC (16 in 99%  yield and 18d in 55% yield) for shorter time (2-3h). Under acidic 
condition, the t-butyl groups on compound 18d were deprotected and 
decarboxylation was observed under reflux to give the monocarboxylated 
derivative. Without purification, the coupling reaction was performed to give 
anilide 20d (yield 99% over three steps). To obtain the final C7-SAHA 
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pyridylmethyl hydroxamic acid 22d, direct conversion was achieved in one step 
(43%). 
 
Scheme 4.3. Redesigned and optimized synthesis for C7-SAHA 
pyridylmethyl analogue 22d 
 
     
4.5 Biological analysis 
HDAC inhibitory activities of the remaining C7-SAHA analogues were 
measured using the Fluor de Lys® in vitro fluorescence activity assay kit using 
Hela cell lysates (Table 4.2). HDAC inhibition of biphenylmethyl variant 22e was 
tested by Geetha Padige. 
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Table 4.2. HDAC inhibition by C7-SAHA analogues and SAHA using HeLa cell 
lysates 
Compounds R IC50, nMª 
SAHA  86  4 
22d 4-Pyridylmethyl 450  35 
22e 4-(1,1'-Biphenyl)methyl 4  0.3 
22f 9-Anthracenylmethyl 20  1 
22g 9-(1,2,3,4-Tetrahydroanthracenyl)methyl 102  30 
ªValues are means of more than three experiments with standard error given. 
 
One of the large compounds, C7-SAHA 4-(1,1´-biphenyl)methyl analogue 
22e displayed greater than 22-fold increase in inhibitory activity compared to 
SAHA (86 nM) or the smallest compound C7-SAHA methyl analogue 22a (105 
nM). Variants 22b, 22e with the large groups, such as naphthylmethyl and 
biphenylmethyl, were more potent than the smallest variant 22a with methyl 
group for C7-SAHA inhibitory activities (Table 4.2). However, the bulky 
tetrahydroanthracenylmethyl subtituents displayed potency similar to SAHA. The 
data suggest that C7-SAHA analogues with planar aromatic groups interacted 
favourably in the binding area of HDAC active site. Moreover, the addition of 
certain groups at the C7 position likely promotes interaction between the 
entrance area of HDAC active site and the inhibitor. 
Even though we found that greater steric tolerance exists in the HDAC 
active site in the entrance area of the capping group than the metal binding 
moiety region, the pyridylmethyl analogue displayed the weakest inhibitory 
activity (IC50 450 nM). The polarity of the nitrogen atom might interact 
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unfavorably the binding area of the HDAC active site. As a result, the potency 
was influenced not only by the size of subsitutuents, but also the polarity, as 
shown by the fact that the pyridylmethyl group of equal size to the benzyl group 
(IC50 109 nM).  
To more thoroughly verify the structural requirements of SAHA analogues, 
the isoform selectivity of the C7-SAHA analogues was tested by using HDAC1 
and HDAC3 representing class I and HDAC6 representing class II (Figure 4.2). 
To assess the isoform selectivity of the C7-SAHA analogues, all compounds 
were initially tested at a single concentration near to their IC50 values using the 
Fluor de Lys® kit (Enzo).  
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Figure 4.2. Screen of C7-SAHA analogues against HDAC1, HDAC3, and HDAC6 with 
100 nM methyl, benzyl, tetrahydroanthracenylmethyl, and biphenylmethyl (22a, 22b, 22g, and 
22e) variants, 500 nM pyridylmethyl and anthracenylmethyl variants (22d and 22f), and 10 nM 
naphthylmethyl variant (22c). 
 
The methyl 22a, and benzyl 22b variants showed similar inhibition for 
HDAC1, HDAC3, and HDAC6 at 100 nM, despite slight selectivity for HDAC6 
over HDAC1 and HDAC3. The biphenyl variant 22e, which displayed the most 
potent inhibition from using Hela cell lysates, showed a slightly preference for 
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HDAC6 over HDAC1 and HDAC3 as well. In this case, however, two flexible 
perpendicular aromatic groups might enhance interaction with all of HDAC 
protein active sites to increase potency, not selectively. In addition, the 
biphenylmethyl variant 22e did not show inhibition at 10 nM concentration near to 
the Hela cell lysate IC50 value (4 nM) for HDAC1, HDAC3, and HDAC6. In 
contrast, the naphthylmethyl 22c and tetrahydroanthracenylmethyl 22g variants 
showed greater potency for HDAC3 over HDAC1 and HDAC6 at 10 nM and 100 
nM. Interestingly, both compounds contain two planar aromatic groups. 
Moreover, the pyridylmethyl 22d and anthracenylmethyl 22f variants showed 
unique dual-selective inhibition at 500 nM for HDAC1 and HDAC6 over HDAC3. 
Surprisingly, the C7-SAHA anthracenylmethyl compound 22f was unable to 
inhibit when tested at 10 nM concentration near to the Hela cell lysate IC50 value 
(20 nM). After several screening, we found that the anthracenylmethyl variant 22f 
inhibited 50% at 500 nM against HDAC1 and HDAC6. The biphenylmethyl 22e 
and anthracenylmethyl 22f variants might display more selective inhibition for 
other HDAC proteins, such as HDAC2, HDAC4, HDAC5, HDAC7, HDAC8, and 
HDAC10 due to the fact that showed inhibition at 25-time higher concentration 
(100 nM and 500 nM) against HDAC1, HDAC3, and HDAC6 than their Hela cell 
lysate IC50 values (4 nM and 20 nM). 
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With the potential of chemotherapeutic use of selective HDAC inhibitors, 
several class-selective and isoform-selective HDAC inhibitors have been studied. 
Most of selective HDAC inhibitors displayed preference for HDAC1 or HDAC8 
against HDAC3.17b, 20, 38b, 57-58  
For example, compounds 27a 
and 27b,  which have two-
aromatic group, showed 
preference for HDAC8 (Figure 4.3).38b Nevertheless, the C7-SAHA 
naphthylmethyl analogue 22c and tetrahydroanthracenylmethyl analogue 22g 
containing similar structures to the compounds 27a and 27b display unique 
HDAC3 selectivity. Two parallel aligned aromatic group subsitutuents on the 
linker region may influence selectivity due to the presence of favorable π-π 
interactions with particular HDAC active site. Additionally, a dual-selective 
HDAC1 and HDAC6 inhibitor (pyridyl 22d and anthracene 22f) might promote 
design of drugs. Therefore, studying the C7-SAHA analogues, which displayed 
HDAC3 selective inhibition (the naphthylmethyl 22c and tetrahydro-
anthracenylmethyl 22g) and dual-HDAC1 and HDAC6 selective inhibition (the 
pyridylmethyl 22d and anthracenylmethyl 22f variants), might be a great starting 
point to develop a variety of dual or isoform-selective HDAC inhibitors. 
To more thoroughly assess the selectivity observed in the initial screen, 
we determined individual HDAC1, HDAC3, and HDAC6 IC50 values of the 
anthracene variant 22f, and SAHA as a comparison. Pathological cardiac 
remodeling studies have been reported using selective HDAC inhibitors (Section 
 
Figure 4.3. HDAC inhibitors modified at the linker regions 
with two parallel aligned aromatic groups  
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1.9). Specifically, development of dual-selective inhibitors has been an attractive 
target in pharmacokinetic study due to the hypothesis by that cancer formation is 
more complex than related to only single isoform HDAC protein. However, a lack 
of information on dual-selective HDAC inhibitors is a current challenge. For 
promising chemotherapeutic use, the anthracenylmethyl analogue 22f among 
C7-SAHA analogues, which displayed dual-selective inhibition for HDAC1 and 
HDAC6, was analyzed by using the Fluor de Lys® kit (Enzo). The C7-
anthracenylmethyl analogue 22f displayed 4-fold selectivity for HDAC1 over 
HDAC3 and 3-fold class selectivity for HDAC6 over HDAC3 (Table 4.3). In 
addition, it displayed selectivity within class I, with 4-fold preference for HDAC1 
over HDAC3. As a control, SAHA displayed non-selective inhibitor activity 
against the isoform, as expected (Table 4.3).30 The selectivity analysis shows 
that substituents on the C7 position can influence selectivity. As a comparison, 
the C6-SAHA t-butyl analogue (dual-HDAC1 and HDAC6 selective inhibitor, IC50 
value of 1.9 µM) displayed 22-fold less potency compared to SAHA (86 nM) while 
the C7-SAHA anthracene analogue 22f (20 nM) showed 4-fold better potency 
compared to SAHA. Therefore, the data indicate that attaching the anthracene 
substituent on the linker chain on the C7 position promotes selectivity with 
potency. 
Table 4.3. IC50 values of SAHA and the C7-SAHA anthracene 22f for HDAC1, 
HDAC3, and HDAC6  
Compound IC50/nM 
HDAC1 HDAC3 HDAC6 
SAHA 96 ± 16 136 ± 11 74 ± 9 
22f 300 ± 66 1200 ± 50 443 ± 73 
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SAHA analogues with substituents on the C7 position displayed selective 
inhibition, including dual-class I, II selectivity (pyridyl 22d and anthracene 22f 
variants) and isoform selectivity for HDAC3 (naphthyl 22c and 
tetrahydroanthracne 22g variants)  and HDAC6 (biphenyl variant 22e). The 
results reveal that small structural changes in the C7 position linker region of 
SAHA will lead in designing drugs by improving selectivity and potency compared 
to the broad-spectrum inhibitor SAHA. Furthermore, studying selective inhibitor 
structures in detail will be able to be explored through our selective compound 
analysis in a variety of scope. 
 
4.6 Future direction 
We have synthesized and analyzed SAHA analogues that placed a variety 
of substituents in the carbon linker. The results from the C3, C6, and C7 library 
suggest that SAHA analogues with substituents on the carbon linker are 
promising to develop new anti-cancer drugs. To more systematically assess the 
structural effect in HDAC active site, more analogues positioning subsituetns at 
the C4, and C5 
positions should 
be synthesized 
(Figure 4.4). In 
addition, analysis of isoform selectivity of the C3-SAHA analogues suggests that 
substituents on the SAHA linker influence selectivity.  We have shown that the 
  
Figure 4.4. Structures of SAHA analogues containing substituents on the  
C4 and C5  
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steric environment of the C6 position displays less influences on potency 
compared to SAHA analogues with substituents near the hydroxamic acid. 
However, substituents at α-carbon on C6 position still decreased inhibitory 
activity. Interestingly, despite the poor potency of the C6-SAHA t-butyl analogue, 
it displayed selectivity. Likewise, the C3-SAHA ethyl analogue with an additional 
methylene group at the α–carbon compared to the C3-SAHA methyl analogue 
displayed selective inhibition (HDAC6 selectivity). The effect of the α-carbon on 
C6 substituents could be thoroughly investigated with the synthesis of isopropyl 
and adamantyl group analogues. Besides, the long chain of the 2-ethyl hexyl 
SAHA analogues on the C6 position also affected isoform selectivity (HDAC3-
selectivity) with potency. Favourable interactions of the long aliphatic chain in 
HDAC active site could be verified through synthesis of C6-SAHA octyl to 
undecyl analogues. Furthermore, C7-SAHA analogues show potent inhibition 
with large and polar group substituents. The influence of the enantiomers with 
bulky or polar groups near the capping group would allow assessing the 
structural requirements of the compounds in detail. Therefore, screening the 
enantiomers of all SAHA analogues might show promising properties. Moreover, 
testing the inhibitory activities against all HDAC proteins, from HDAC1 to 
HDAC11, will provide the structures of selective inhibitors. Developing new cost-
effective, high through-put screening methods are needed to test selectivity 
against all HDAC1-11. Therefore, the biological evaluation of the current 
compound enantiomers, the additional synthesis of different structural 
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compounds, and the development of easy-access high through-put assay will 
contribute to develop promising cancer drugs. 
4.7 Experimental 
4.7.1 General methods 
Additional details were shown in Section 2.5.1 of Chapter 2. 
4.7.2 Experimental Procedures and Compound Characterizations 
 
 
1, 1-Dibenzyl 6-methyl hexane-1, 1, 6-tricarboxylate (24). To a solution of NaH 
(144 mg, 6 mmol) in DMF (20 mL) was added dibenzylmalonate (1.14 mL, 6 
mmol) dropwise at 0 ºC and the mixture was stirred for 15 min. To the solution 
was added methyl 6-bromohexanoate 23 (0.57 g, 2 mmol) and the mixture was 
stirred for 3 h. The mixture was filtered through celite with ethyl acetate and 
concentrated. The residue was purified by column chromatography (diethyl 
ether:petroleum ether 1:19) on silica gel to give 24 (682 mg, 81%).  1H-NMR (δ, 
ppm, CHLOROFORM-D): 1.31 (m, 4H), 1.58 (m, 2H), 1.94 (q, 2H), 2.26 (t, 2H), 
3.43 (t, 1H), 3.65 (s, 3H), 5.14 (s, 4H), 7.31 (m, 10H); 13C-NMR (δ, ppm, 
CHLOROFORM-D): 24.8, 27.1, 28.8, 28.9, 34.1, 51.7, 52.1, 67.3, 128.4, 128.6, 
128.8, 135.6, 169.4, 174.3; IR: 3033, 2949, 2862, 1734, 1498, 1456, 1333, 1214, 
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1156, 907, 741, 698 cm-1; HRMS (EI-TOF, m/z): found [M+Na] 435.1767, calc. 
for C24H28O6, 435.1784. 
 
6, 6-Dibenzyl 1-methyl 7-(pyridine-4-yl)heptane-1, 6, 6-tricarboxylate (25). To 
a solution of NaH (256 mg, 6.4 mmol) in DMF (53 mL) was added 1, 1-dibenzyl 
6-methyl hexane-1, 1, 6-tricarboxylate 24 (2.20 g, 5.33 mmol) dropwise at 0 ºC 
and the mixture was stirred for 15 min. Separately, 1.5 equivalents of 4-bromo-
methylpyridine hydrobromide salt (2.02 g, 8.00 mmol) was dissolved in distilled 
water (8 mL) and added to a separatory funnel, followed by 0.7 equivalent of 
Na2CO3 (396 mg, 3.74 mmol). After the separatory funnel was shaken until gas 
evolution was not observed, the mixture was extracted with ethyl acetate (8 mL) 
at least 4 times. The organic layers were dried over magnesium sulfate, filtered, 
and concentrated by rotary evaporation. To the flask containing the activated 
dibenzyl malonate derivatives solution 24 was added the solution of the 
neutralized and concentrated 4-bromo-methylpyridine and the mixture was stirred 
for 4h at 0 ºC. The reaction was quenched with distilled water (26.5 mL) and 
extracted with ethyl acetate (equal volume to aqueous layer). The organic layer 
was pooled and extracted with distilled water (equal volume to organic layer) at 
least 4 times. The organic layer was dried over magnesium sulfate, filtered, and 
concentrated to oil. The residue was purified by column chromatography (ethyl 
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acetate:hexanes 1:3) on silica gel to give 25 (1.61 g, 60%).  1H-NMR (δ, ppm, 
CHLOROFORM-D): 1.21 (m, 4H), 1.50 (m, 2H), 1.75 (t, 2H), 2.20 (t, 2H), 3.19 (s, 
2H), 3.64 (s, 3H), 5.08 (s, 4H), 6.82 (d, 1H), 6.91 (d, 1H), 7.24-7.31 (m, 7H), 8.35 
(d, 1H), 8.36 (d, 1H); 13C-NMR (δ, ppm, CHLOROFORM-D): 24.1, 24.8, 29.3, 
32.3, 34.0, 37.8, 51.7, 58.7, 67.5, 125.3, 128.765, 128.787, 128.816, 135.3, 
145.3, 149.9, 170.6, 174.1; IR: 3032, 2951, 1731, 1601, 1455, 1218, 1170,  912, 
733, 698 cm-1; HRMS (EI-TOF, m/z): found [M+H] 504.2387, calc. for C30H34NO6, 
504.2386. 
 
 
 
Benzyl 6-bromohexanoate (16). Benzyl alcohol (0.07 mL, 0.68 mmol) and 
concentrated aqueous sulfuric acid (3 µL, 0.056 mmol) were stepwise added to a 
solution of 6-bromohexanoic acid 15 (0.11 g, 0.56 mmol) in diethyl ether (5 mL) 
at 0ºC. The mixture was stirred for 30min and warmed to room temperature. The 
reaction mixture was quenched with distilled water (5 mL). The mixture was 
extracted with diethyl ether (5 mL) at least 4 times. The organic layer was 
evaporated. The concentrated organic layer was extracted with distilled water 
(equal volume to the concentrated organic layer) at least 3 times. The organic 
layer was dried over anhydrous Na2SO4, filtered, and concentrated. The residue 
was purified by column chromatography (diethyl ether:petroleum ether 1:19) on 
silica gel to give 16 (153 mg, 95%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.47 
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(m, 2H), 1.68 (m, 2H), 1.86 (m, 2H), 2.38 (t, 2H), 3.38 (t, 2H), 5.12 (s, 2H), 7.36 
(m, 5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 24.3, 27.9, 32.6, 33.7, 34.3, 
66.4, 128.5, 128.8, 136.3, 173.5; IR: 3033, 2939, 1733, 1455, 1254, 1165, 736, 
697 cm-1; HRMS (EI-TOF, m/z): found [M+Na] 307.0314, calc. for C13H17O2NaBr, 
307.0310. 
 
6-Benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate (17). To a solution of 
NaH (589 mg, 14.7 mmol) in DMF (49 mL) was added di-t-butylmalonate (3.30 
mL, 14.7 mmol) dropwise at 0 ºC and the mixture was stirred for 15 min. To the 
solution was added benzyl 6-bromohexanoate 16 (1.4 g, 4.91 mmol) at 0 ºC and 
the mixture was stirred for 3 h at room temperature. The mixture was filtered 
through celite with ethyl acetate and concentrated. The residue was purified by 
column chromatography (diethyl ether:petroleum ether 1:19) on silica gel to give 
17 (2.04 g, 99%).1H-NMR (δ, ppm, CHLOROFORM-D): 1.34 (m, 4H), 1.45 (s, 
18H), 1.65 (m, 2H), 1.79 (q, 2H), 2.34 (t, 2H), 3.10 (t, 1H), 5.11 (s, 2H), 7.35 (m, 
5H); 13C-NMR (δ, ppm, CHLOROFORM-D): 24.9, 27.1, 28.2, 28.6, 29.0, 34.4, 
54.1, 66.3, 81.5, 128.4, 128.8, 135.6, 169.1, 173.7; IR: 3033, 2979, 2935, 2861, 
1729, 1498, 1369, 1256, 1169, 1139, 748 cm-1; found MS(ESI): m/z = 427.30 
(M++Li), 443.30 (M++Na), 459.27 (M++K), calc. for C24H36LiO6, 427.48, 
C24H36NaO6, 443.53, C24H36KO6, 459.64. 
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1-Benzyl 6,6-di-tert-butyl 7-(pyridine-4-yl)heptane-1,6,6-tricaboxylate (18d). 
To NaH (171 mg, 4.28 mmol) and  4-bromo-methylpyridine hydrobromide salt 
(1.0 g, 4.28 mmol) was added DMF (16 mL) dropwise at 0 ºC and the mixture 
was stirred for 20min. Separately, to NaH (171 mg, 4.28 mmol) in DMF (20 mL) 
was added 6-benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate 17 (1.5 g, 3.57 
mmol) dropwise at 0 ºC and the mixture was stirred for 20 min. To the solution of 
the activated 6-benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate 17 was added 
the solution of the neutralized 4-bromo-methylpyridine dropwise at 0 ºC and the 
mixture was stirred for 3h at room temperature. The reaction mixture was filtered 
through celite with ethyl acetate and concentrated. The residue was purified by 
column chromatography (diethyl ether:petroleum ether 1:5) on silica gel to give 
18d (513 mg, 55%). 1H-NMR (δ, ppm, CHLOROFORM-D): 1.29 (m, 4H), 1.43 (s, 
18H), 1.65 (m, 4H), 2.34 (t, 2H), 3.12 (s, 2H), 5.10 (s, 2H), 7.07 (d, 2H), 7.34 (m, 
5H), 8.47 (d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-D): 24.0, 24.9, 28.1, 29.5, 
32.2, 34.4, 37.4, 59.1, 66.4, 82.0, 125.6, 128.4, 128.8, 136.2, 146.3, 149.7, 
170.3, 173.6; IR: 3036, 2976, 2935, 2867, 1727, 1605, 1248, 1159, 846, 737, 
696 cm-1; HRMS (EI-TOF, m/z): found [M+H] 512.3016, calc. for C30H42NO6, 
512.3012. 
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Benzyl 8-oxo-8-(phenylamino)-7-(pyridine-4-ylmethyl)octanoate  (20d). To a 
flask equipped with a reflux condenser and containing 1-benzyl 6,6-di-tert-butyl 
7-(pyridine-4-yl)heptane-1,6,6-tricaboxylate 18d (510 mg, 997 mmol) was added 
10 mL of 10% TFA in acetic acid. The reaction mixture was refluxed overnight 
and evaporated to oil. The residue was dissolved in ethyl acetate (10 mL) and 
transferred to a separatory funnel. The solution was extracted with saturated 
NaHCO3(aq) (equal volume to organic layer) at least 4 times. The organic layer 
was dried over magnesium sulfate, filtered, and evaporated. The crude residue 
was dissolved in acetonitrile (10 mL). To the solution of crude carboxylic acid 
derivative was added individually in order listed in a stepwise: TBTU (480 mg), 
diisopropylethylamine (695 mL), and aniline (136 mL). The reaction mixture was 
stirred overnight at room temperature. The reaction was quenched by addition of 
an aqueous solution of saturated NaHCO3 (10 mL). The mixture was extracted 
with CH2Cl2 (equal volume to aqueous layer) at least 4 times. The organic layer 
was dried over magnesium sulfate, filtered, and concentrated to an oil. The 
residue was purified by column chromatography (ether:petroleum ether 1:1) on 
silica gel to give 20d (572 mg, 99%).  1H-NMR (δ, ppm, CHLOROFORM-D): 
1.34  (m, 4H), 1.49 (m, 1H), 1.61 (m, 2H), 1.79 (m, 1H), 2.33 (t, 2H), 2.47 (m, 
1H), 2.69 (q, 1H), 3.02 (q, 1H), 5.09 (s, 2H), 7.09 (m, 3H), 7.25 (m, 2H), 7.32 (m, 
4H), 7.38 (d, 2H), 7.89 (m, 1H), 8.40 (d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-
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D): 24.8, 27.1, 29.0, 33.1, 34.3, 38.6, 49.9, 66.4, 120.4, 124.7, 128.3, 128.4, 
128.5, 128.8, 129.2, 136.2, 137.9, 149.4, 149.8, 173.0, 173.9; IR: 3304, 3221, 
3035, 2931, 2858, 1734, 1602, 1443, 1173, 912, 752, 696 cm-1. HRMS (EI-TOF, 
m/z): found [M+H] 431.2331, calc. for C27H31N2O3, 431.2335. 
 
N8-hydroxy-N1-phenyl-2-(pyridin-4-ylmethyl)octanediamide (22d). To a 
solution of NH2OH∙HCl (536 mg, 7.67 mmol) in methanol (8 mL) was added KOH 
(860 mg, 15.3 mmol) at 0 ˚C in an acid-washed 25mL round-bottom flask.  After 
stirring for 20 min, benzyl 8-oxo-8-(phenylamino)-7-(pyridine-4-
ylmethyl)octanoate  20d (330 mg, 0.767 mmol) was added and the mixture was 
stirred for 8h at 0°C. The reaction mixture was quenched by adding 1mL of 
distilled water and adjusting to pH 6 by adding concentrated aqueous 
hydrochloric acid. The mixture was diluted with 8 mL of ethyl acetate, and 
extracted with distilled water (equal volume to organic layer) at least 4 times. The 
organic layer was dried over magnesium sulfate, filtered and concentrated. The 
residue was purified by column chromatography (8% methanol/CH2Cl2 with 0.1% 
Et3N) on acid-washed silica gel to give 22d (116 mg, 43%). 
1H-NMR (δ, ppm, 
METHANOL-D): 1.39 (m, 4H), 1.60 (m, 3H), 1.77 (m, 1H), 2.08 (t, 2H), 2.86 (m, 
2H), 2.93-3.00 (m, 2H), 7.06 (t, 1H), 7.25 (t, 2H), 7.43 (d, 2H), 7.50 (d, 2H), 8.48 
(d, 2H); 13C-NMR (δ, ppm, CHLOROFORM-D): 25.4, 26.9, 28.8, 32.4, 32.8, 38.4, 
120.3, 124.3, 125.8, 128.6, 138.1, 146.7, 153.8, 171.7, 174.1; IR: 3440, 3335, 
98 
2866, 1720, 1641, 1528, 1442, 1133, 759, 660 cm-1; HRMS (EI-TOF, m/z): found 
[M+H] 356.1966, calc. for C20H26N3O3, 356.1974. HPLC analytical purity analysis: 
90%. 
 
 
4.8 HDAC assay procedure 
HDAC activity was measured using the Fluor de Lys® activity assay 
(Biomol & Enzo) using the manufacturer’s protocol. Additional details were 
shown in Section 3.6 of Chapter 3. 
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APPENDIX A. DOSE RESPONSE GRAPHS AND DATA FOR C3-SAHA 
LIBRARY 
 
Figure A.1. Dose response curve of C3-SAHA analogue 1a-e tested using the 
HDAC activity from HeLa cells lysates from three independent trials with error 
bars indicating standard error. In some case, the error bars are smaller than the 
marker size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) to determine the IC50. The insets were the results of the data 
analysis. The data are reported in Table 2.1.   
 
Table A.1 Inhibition of HDAC Activity of SAHA C3-Butyl with Hela Lysate 
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
3.125 x 10
-5
 83 85 81 83 1 
6.25 x 10
-5
 72 69 73 71 1 
1.25 x 10
-4
 54 54 51 53 1 
2.50 x 10
-4
 47 46 46 46 1 
5.00 x 10
-4
 31 35 34 33 1 
1.00 x 10
-4
 19 22 20 20 1 
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Table A.2 Inhibition of HDAC Activity of SAHA C3-Phenyl with Hela Lysate 
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.00 x 10
-6
 98 80 86 88 5 
1.5625 x 10
-5
 88 79 74 80 4 
3.125 x 10
-5
 74 65 66 68 3 
6.25 x 10
-5
 59 54 50 54 3 
1.25 x 10
-4
 40 38 38 37 1 
2.50 x 10
-4
 25 26 24 25 1 
5.00 x 10
-4
 15 14 14 14 1 
 
Table A.3 Inhibition of HDAC Activity of C3-SAHA Ethyl with Hela Lysate 
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.00 x 10
-6
 88 85 82 85 2 
7.8125 x 10
-5
 75 69 67 70 2 
1.5625 x 10
-5
 67 62 61 63 1 
3.125 x 10
-5
 52 57 57 55 2 
6.25 x 10
-5
 42 46 34 41 4 
1.25 x 10
-4
 27 28 28 28 1 
2.50 x 10
-4
 18 15 14 16 1 
 
Table A.4 Inhibition of HDAC Activity of SAHA C3-Vinyl with Hela Lysate 
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.00 x 10
-6
 84 75 99 86 7 
3.906 x 10
-6
 83 60 69 71 7 
7.8125 x 10
-6
 72 55 57 61 5 
1.5625 x 10
-5
 60 43 47 50 5 
3.125 x 10
-5
 48 34 37 40 4 
6.25 x 10
-5
 32 23 27 27 3 
 
Table A.5 Inhibition of HDAC Activity of C3-SAHA Methyl with Hela Lysate 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.00 x 10
-9
 95 93 77 88 4 
6.25 x 10
-8
 85 75 72 77 4 
1.25 x 10
-7
 77 72 62 72 3 
2.50 x 10
-7
 62 58 54 58 2 
5.00 x 10
-7
 45 46 43 44 1 
1.00 x 10
-6
 31 28 29 29 1 
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Table A.6 Isoform Selective HDAC Inhibition of SAHA C3 Analogues 
 
Compound 
 
HDAC 
Isoform 
Trial 1 Trial 2 Mean S.E 
 
SAHA 
(125 nM) 
 
HDAC1 27 35 31 4 
HDAC3 44 45 45 1 
HDAC6 32 37 35 3 
 
C3-Methyl 
(375 nM) 
HDAC1 44 47 46 2 
HDAC3 53 62 57 5 
HDAC6 73 75 74 1 
 
C3-Ethyl 
(32 µM) 
HDAC1 38 39 39 1 
HDAC3 71 95 83 12 
HDAC6 17 18 18 1 
 
C3-Vinyl 
(32 µM) 
HDAC1 23 26 25 2 
HDAC3 47 51 49 2 
HDAC6 26 28 27 1 
 
C3-Butyll 
(32 µM) 
HDAC1 33 33 33 0 
HDAC3 52 52 52 0 
HDAC6 22 25 24 2 
 
C3-Phenyl 
(32 µM) 
 
HDAC1 42 48 45 3 
HDAC3 50 51 51 1 
HDAC6 24 27 26 2 
 
Deacetylase activity of HDAC1, HDAC3 and HDAC6 was determined with SAHA 
and with SAHA C3 analogs at given concentration using an in vitro fluorescence 
assay as described. The background fluorescence activity (No enzyme added) 
was subtracted and the percentage deacetylase activity was calculated with 
compared to the No small molecule treated (100%). Percentage deacetylase 
activity of each independent trial, mean percentage deacetylase activity and 
standard error (S.E) are shown. 
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Figure A.2. Dose response curves of SAHA tested against HDAC1, HDAC3, and 
HDAC6 from three independent trials with error bars indicating standard error. In 
some cases, the error bars are smaller than the marker size.  The data is 
reported in the manuscript in Table 2.2.   
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Figure A.3. Dose response curves of the C3- SAHA ethyl analogue 1c tested 
against HDAC1, HDAC3, and HDAC6 from three independent trials with error 
bars indicating standard error. In some cases, the error bars are smaller than the 
marker size.  The data is reported in the manuscript in Table 2.2.   
 
Table A.7 Inhibition of HDAC1 Activity by SAHA  
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
3.125 x 10
-8
 68 91 82 80 7 
6.25 x 10
-8
 55 62 57 58 2 
1.25 x 10
-7
 48 27 37 37 6 
2.50 x 10
-7
 37 40 25 34 5 
 
Table A.8 Inhibition of HDAC3 Activity by SAHA  
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
3.125 x 10
-8
 88 78 74 80 4 
6.25 x 10
-8
 76 74 70 73 2 
1.25 x 10
-7
 63 45 44 56 5 
2.50 x 10
-7
 27 39 37 34 4 
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Table A.9 Inhibition of HDAC6 Activity by SAHA  
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
3.125 x 10
-8
 66 76 73 72 3 
6.25 x 10
-8
 64 62 60 62 1 
1.25 x 10
-7
 37 28 32 32 2 
2.50 x 10
-7
 13 12 9 11 1 
 
  
Table A.10 Inhibition of HDAC1 Activity by SAHA C3-Ethyl  
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.00 x 10
-6
 102 89 ND 96 9 
7.8125 x 10
-6
 83 94 86 88 6 
1.5625 x 10
-5
 58 65 51 58 7 
3.125 x 10
-5
 39 38 ND 39 1 
 
  
Table A.11 Inhibition of HDAC3 Activity by SAHA C3-Ethyl  
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
3.125 x 10
-5
 95 71 ND 83 12 
62.50 x 10
-5
 58 57 66 60 3 
1.25 x 10
-4
 46 35 53 45 5 
2.50x 10
-5
 20 21 25 22 2 
 
Table A.12 Inhibition of HDAC6 Activity by SAHA C3-Ethyl  
 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E 
1.000 x 10
-6
 81 76 78 78 1 
3.906 x 10
-6
 69 65 64 66 2 
7.812 x 10
-6
 52 58 51 54 2 
1.562 x 10
-5
 38 40 38 39 1 
3.125 x 10
-5
 17 18 ND 18 1 
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APPENDIX B. SUPPLEMENTARY INFORMATION FOR C3-SAHA LIBRARY  
B.1 5-Hydroxy-N-phenylpentanamide (3) 
B.1.1 
1
H NMR                           
 
B.1.2 
13
C NMR             
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B.1.3 IR                                      
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B.1.4 HRMS 
 
 
B.2 6-Oxo-6-(phenylamino)hexanal (4) 
B.2.1 
1
H NMR                         
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B.2.2 
13
C NMR                        
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B.2.3 IR                       
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B.2.4 HRMS 
 
B.3 8-Oxo-8-(phenylamino)-oct-2-enoate (5) 
B.3.1 
1
H NMR (E)                     
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B.3.2 
1
H NMR (Z)                        
                     
B.3.3
 13
C NMR                              
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B.3.4 IR                                  
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B.3.5 HRMS 
 
B.4 8-Oxo-8-(phenylamino)-3-n-butyloctanoate (6a) 
B.4.1 
1
H NMR 
 
 114  
 
B.4.2 
13
C NMR              
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B.4.3 IR                                  
 
 116  
 
B.4.4 HRMS 
 
B.5 8-Oxo-8-(phenylamino)-3-phenyloctanoate (6b) 
B.5.1 
1
H NMR  
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B.5.2 
13
C NMR          
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B.5.3 IR          
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B.5.4 HRMS 
 
B.6 8-Oxo-8-(phenylamino)-3-ethyloctanoate (6c) 
B.6.1 
1
H NMR  
 
 120  
 
B.6.2 
13
C NMR     
 
 121  
 
B.6.3 IR  
 
 122  
 
B.6.4 HRMS 
 
B.7 8-Oxo-8-(phenylamino)-3-vinyloctanoate (6d) 
B.7.1 
1
H NMR    
 
 123  
 
B.7.2 
13
C NMR  
 
 124  
 
B.7.3 IR    
 
 125  
 
B.7.4 HRMS 
 
B.8 8-Oxo-8-(phenylamino)-3-methyloctanoate (6e) 
B.8.1 
1
H NMR   
    
 126  
 
B.8.2 
13
C NMR   
 
B.8.3 IR   
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B.8.1 HRMS 
 
B.9 3-n-Butyl-N
1
-hydroxyl-N
8
-phenyloctanoic acid (7) 
B.9.1 
1
H NMR     
 
 128  
 
B.9.2 
13
C NMR  
 
 129  
 
B.9.3 IR            
 
B.9.4 HRMS 
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B.10 3-n-Butyl-N
1
-benzyloxy-N
8
-phenyloctanediamide (8) 
B.10.1 
1
H NMR   
    
 
 131  
 
B.10.2 
13
C NMR    
 
 132  
 
B.10.3 IR   
 
 133  
 
B.10.4 HRMS 
 
B.11 3-n-Butyl-N
1
-hydroxyl-N
8
-phenyloctandiamide (1a) 
B.11.1 
1
H NMR    
 
 134  
 
B.11.2 
13
C NMR    
 
 135  
 
B.11.3 IR               
 
B.11.4 HRMS 
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B.11.5 HPLC         
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B.12 3-Phenyl-N
1
-hydroxyl-N
8
-phenyloctandiamide (1b) 
B.12.1 
1
H NMR              
 
B.12.2 
13
C NMR    
 
 138  
 
B.12.3 IR               
 
 139  
 
B.12.4 HRMS 
 
B.12.5 HPLC       
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B.13 3-Ethyl-N
1
-hydroxyl-N
8
-phenyloctandiamide (1c) 
B.13.1 
1
H NMR    
 
B.13.2 
13
C NMR      
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B.13.3 IR      
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B.13.4 HRMS  
 
B.13.5 HPLC        
4
.6
6
8
A
U
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
0.80
0.90
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
1
RT Area % Area Height
4.668 7510006 100.00 924974
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B.14 3-Vinyl-N
1
-hydroxyl-N
8
-phenyloctandiamide (1d) 
B.14.1 
1
H NMR     
 
B.14.2 
13
C NMR      
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B.14.3 IR    
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B.14.4 HRMS   
 
B.14.5 HPLC         
9
.4
8
9
9
.8
2
1
1
0
.1
5
6
A
U
0.00
0.50
1.00
1.50
2.00
2.50
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
1
2
3
RT Area % Area Height
9.489
9.821
10.156
888985
803374
25352757
3.29
2.97
93.74
135811
134069
2759849
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B.15 3-Methyl-N
1
-hydroxyl-N
8
-phenyloctandiamide (1e) 
B.15.1 
1
H NMR   
 
B.15.2 
13
C NMR        
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B.15.3 IR   
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B.15.4 HRMS  
 
B.15.5 HPLC      
1
1
.9
5
0
1
3
.4
7
5
A
U
0.00
0.50
1.00
1.50
2.00
2.50
3.00
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
1
2
3
4
5
6
Peak Name RT Area % Area Height
Peak2
Peak3
Peak4
Peak1
9.489
9.821
10.156
10.871
11.950
13.475
1469677
57777809
2.48
97.52
129416
3069522
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APPENDIX C. DOSE RESPONSE GRAPHS AND DATA FOR C6-SAHA 
LIBRARY 
 
Table C.1. Percentage HDAC activity after incubation of SAHA with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard  
Error (S.E.) 
3.125 x 10
-8
 75 75 ND 75 0 
6.25 x 10
-8
 63 56 51 57 3 
1.25 x 10
-7
 44 35 40 40 3 
2.5 x 10
-7
 31 21 26 26 3 
5.0 x 10
-7
 20 16 15 17 2 
 
 
Figure C.1. Dose response curve of SAHA tested using the HDAC activity from 
HeLa cells lysates from three independent trials In some case, the error bar is 
smaller than the marker size. Data were fit to the sigmoidal curve using 
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets were the 
results of the data analysis. The data are reported in Table 3.1.   
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Table C.2. Percentage HDAC activity after incubation of MS-275 with Hela 
Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.95 x 10
-6
 58 59 58 58 0.3 
3.91 x 10
-6
 44 47 49 47 1 
7.81 x 10
-6
 32 35 33 33 1 
1.56 x 10
-5
 27 27 26 27 0.3 
6.25 x 10
-5
 9 12 11 11 1 
 
 
 
Figure C.2. Dose response curve of MS-275 tested using the HDAC activity from 
HeLa cells lysates from three independent trials. In some cases, the error bars 
are smaller than the marker size. Data were fit to the sigmoidal curve using 
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets were the 
results of the data analysis. The data are reported in Table 3.1.  
 
 
 
 151  
 
 
 
  
Table C.3. Percentage HDAC activity after incubation of C6-SAHA methyl 
analogue 14a with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
6.25 x 10
-8
 104 72 102 92 10 
1.25 x 10
-7
 94 50 85 76 13 
2.5 x 10
-7
 66 51 79 65 8 
5.0 x 10
-7
 30 32 40 34 3 
1.0 x 10
-6
 24 20 22 22 1 
 
 
 
Figure C.3. Dose response curve of C6-SAHA methyl analogue 14a tested using 
the HDAC activity from HeLa cells lysates from three independent trials. In some 
case, the error bar is smaller than the marker size. Data were fit to the sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
insets were the results of the data analysis. The data are reported in Table 3.1.   
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Table C.4. Percentage HDAC activity after incubation of C6-SAHA phenyl 
analogue 14b with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
6.25 x 10
-8
 87 87 82 85 1 
1.25 x 10
-7
 75 73 75 74 0.7 
2.5 x 10
-7
 59 41 54 51 5 
5.0 x 10
-7
 45 47 51 47 1 
1.0 x 10
-6
 27 23 20 23 2 
 
 
Figure C.4. Dose response curve of C6-SAHA phenyl analogue 14b tested 
using the HDAC activity from HeLa cells lysates from three independent trials 
with error bars indicating standard error. In some case, the error bar is smaller 
than the marker size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) to determine the IC50. The insets were the results of the data 
analysis. The data are reported in Table 3.1.   
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Table C.5. Percentage HDAC activity after incubation of C6-SAHA t-butyl 
analogue 14c with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.11 x 10
-7
 94 99 114 102 6 
3.33 x 10
-7
 65 87 103 85 11 
1.0 x 10
-6
 55 58 71 61 4 
3.0 x 10
-6
 40 37 41 39 1 
9.0 x 10
-6
 28 20 18 22 3 
 
 
Figure C.5. Dose response curve of C6-SAHA t-butyl analogue 14c tested using 
the HDAC activity from HeLa cells lysates from three independent trials. In some 
case, the error bar is smaller than the marker size. Data were fit to the sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
insets were the results of the data analysis. The data are reported in Table 3.1.   
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Table C.6. Percentage HDAC activity after incubation of C6-SAHA 2-ethylhexyl 
analogue 14d with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.11 x 10
-7
 93 69 78 80 7 
3.33 x 10
-7
 62 54 55 57 2 
1.0 x 10
-6
 42 22 38 34 6 
3.0 x 10
-6
 12 8 13 11 1 
9.0 x 10
-6
 4 2 2 2.7 0.7 
 
 
Figure C.6. Dose response curve of C6-SAHA 2-ethylhexyl analogue 14d tested 
using the HDAC activity from HeLa cells lysates from three independent trials 
with error bars indicating standard error. In some case, the error bar is smaller 
than the marker size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) to determine the IC50. The insets were the results of the data 
analysis. The data are reported in Table 3.1.   
 155  
 
Table C.7.  Deacetylase activity percentage remaining after incubation of 
HDAC1, HDAC3, or HDAC6 with SAHA or the C6-SAHA analogues 14a-e.
 
Compound 
 
HDAC 
Isoform 
Trial 1 Trial 2 Mean S.E. 
 
SAHA 
(125 nM) 
HDAC1 30 35 32 2 
HDAC3 44 45 44 1 
HDAC6 32 36 34 2 
 
C6-Methyl 
(500 nM) 
HDAC1 35 42 38 3 
HDAC3 32 33 32 0.5 
HDAC6 61 58 59 1 
 
C6-Phenyl 
(500 nM) 
HDAC1 57 56 56 0.5 
HDAC3 68 67 67 0.5 
HDAC6 61 58 59 1 
 
C6-t-Butyl 
(2 µM) 
HDAC1 44 46 45 1 
HDAC3 79 82 80 1 
HDAC6 56 55 55 0.5 
 
C6-2-Ethylhexyl 
(500 nM) 
HDAC1 77 73 75 2 
HDAC3 51 54 52 1 
HDAC6 91 95 93 2 
 
C6-Isopropyl 
(µM) 
HDAC1 42 48 45 3 
HDAC3 50 51 51 1 
HDAC6 24 27 26 2 
 
Deacetylase activity of HDAC1, HDAC3 and HDAC6 was determined with SAHA 
and with C6-SAHA analogues at given concentration using an in vitro 
fluorescence assay as described (Section 3.6). The fluorescence activity of 
background (No enzyme added) was subtracted from the no small molecule 
treated (positive control) and the percentage of the deacetylase activity was set 
to 100%.  Deacetylase activity percentage of each independent trial, mean 
percentage of deacetylase activity, and standard error (S.E.) are illustrated. The 
data are reported in the manuscript in Figure 3.2. 
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Table C.8. HDAC1 activity percentage after incubation of SAHA. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 68 91 82 80 7 
6.25 x 10
-8
 55 62 57 58 2 
1.25 x 10
-7
 48 27 37 37 6 
2.50 x 10
-7
 37 40 25 34 5 
 
 
 
Figure C.7. Dose response curve of SAHA tested using the HDAC1 activity from 
three independent trials with error bars indicating standard error. Data were fit to 
the sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the 
IC50. The insets were the results of the data analysis. The data are reported in 
Table 3.2.   
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Table C.9. HDAC3 activity percentage after incubation of SAHA. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 88 78 74 80 4 
6.25 x 10
-8
 76 74 70 73 2 
1.25 x 10
-7
 63 45 44 56 5 
2.50 x 10
-7
 27 39 37 34 4 
 
 
Figure C.8. Dose response curve of SAHA tested using the HDAC3 activity from 
three independent trials with error bars indicating standard error. Data were fit to 
the sigmoidal curve using Kaleidograph 4.0 (Synergy Software) to determine the 
IC50. The insets were the results of the data analysis. The data are reported in 
Table 3.2.   
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Table C.10. HDAC6 activity percentage after incubation of SAHA. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 66 76 73 72 3 
6.25 x 10
-8
 64 62 60 62 1 
1.25 x 10
-7
 37 28 32 32 2 
2.50 x 10
-7
 13 12 9 11 1 
 
 
 
Figure C.9. Dose response curve of SAHA tested using the HDAC6 activity from 
three independent trials with error bars indicating standard error. In some case, 
the error bars are smaller than the marker size. Data were fit to the sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
insets were the results of the data analysis. The data are reported in Table 3.2.   
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Table C.11. HDAC1 activity percentage after incubation of C6-SAHA t-butyl 
analogue 14c. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
2.50 x 10
-7
 102 92 82 92 5 
5.00 x 10
-7
 86 85 80 84 1 
1.00 x 10
-6
 68 44 35 49 9 
3.125 x 10
-5
 7 1 1 3 2 
 
 
Figure C.10. Dose response curve of C6-SAHA t-butyl analogue 14c tested 
using the HDAC1 activity from three independent trials with error bars indicating 
standard error. Data were fit to the sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) to determine the IC50. The insets were the results of the data 
analysis. The data are reported in Table 3.2.   
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Table C.12. HDAC3 activity percentage after incubation of C6-SAHA t-butyl 
analogue 14c. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.00 x 10
-6
 87 85 81 84 1 
4.00 x 10
-6
 76 63 52 64 6 
1.5625 x 10
-5
 21 20 13 18 2 
3.125 x 10
-5
 7 6 6 6 - 
 
 
Figure C.11. Dose response curve of C6-SAHA t-butyl analogue 14c tested 
using the HDAC3 activity from three independent trials. In some case, the error 
bar is smaller than the marker size. Data were fit to the sigmoidal curve using 
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets were the 
results of the data analysis. The data are reported in Table 3.2.   
 
 
 
 
 
 161  
 
 
Table C.13. HDAC6 activity percentage after incubation of C6-SAHA t-butyl 
analogue 14c. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
5.00 x 10
-7
 98 90 88 92 3 
1.00 x 10
-6
 89 82 86 85 2 
2.00 x 10
-6
 48 35 48 44 4 
4.00 x 10
-6
 45 29 45 40 5 
 
 
Figure C.12. Dose response curve of C6-SAHA t-butyl analogue 14c tested 
using the HDAC6 activity from three independent trials with error bars indicating 
standard error. Data were fit to the sigmoidal curve using Kaleidograph 4.0 
(Synergy Software) to determine the IC50. The insets were the results of the data 
analysis. The data are reported in Table 3.2.   
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APPENDIX D. SUPPLEMENTARY INFORMATION FOR C6-SAHA LIBRARY 
D.1 Methyl 6-hydroxyhexanoate (9) 
D.1.1
 1
H NMR    
                        
D.1.2
 13
C NMR      
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D.1.3 IR                                     
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D.1.4 HRMS                                       
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D.2 1-Benzyl 8-methyl oct-2-enedioate (11) 
D.2.1 
1
H NMR   
                      
D.2.2 
13
C NMR    
                     
 166  
 
D.2.3 IR                          
 
 167  
 
D.2.4 HRMS                                              
 
 
D.3 1-Benzyl 8-methyl 3-methyloctanedioate (12a)  
D.3.1 
1
H NMR     
            
 168  
 
D.3.2 
13
C NMR     
 
     
D.3.3 HRMS 
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D.4 1-Benzyl 8-methyl 3-(tert-butyl)octanedioate (12c) 
D.4.1 
1
H NMR    
          
 170  
 
D.4.2 
13
C NMR     
          
 171  
 
D.4.3 IR                           
                    
 172  
 
D.4.4 LRMS [M+Li]                      
 
D.5 1-Benzyl 8-methyl 3-(2-ethylhexyl)octanedioate (12d) 
D.5.1 
1
H NMR   
               
 173  
 
D.5.2 
13
C NMR 
 
 174  
 
D.5.3 IR                                          
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D.5.4 LRMS [M+K], [M+Li], and [M+Na]                          
 
D.6.1 1-Benzyl 8-methyl 3-isopropyloctanedioate (12e) 
D.6.1 
1
H NMR  
 
 176  
 
D.6.2 
13
C NMR  
 
 177  
 
D.6.3 IR                                         
 
 178  
 
D.6.4 HRMS                  
    
D.7 Methyl 6-methyl-8-oxo-8-(phenylamino)octanoate (13a) 
D.7.1 
1
H NMR  
 
 179  
 
D.7.2 
13
C NMR  
 
 180  
 
D.7.3 IR                                                       
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D.7.4 HRMS                          
           
D.8 Methyl 6-(tert-butyl)-8-oxo-8-(phenylamino)octanoate (13c) 
D.8.1 
1
H NMR  
 
 182  
 
D.8.2 
13
C NMR   
 
D.8.3 IR                                
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D.8.4 HRMS                                       
  
D.9 Methyl 8-ethyl-6-(2-oxo-2-(phenylamino)ethyl)dodecanoate (13d) 
D.9.1 
1
H NMR   
 
 184  
 
D.9.2 
13
C NMR   
 
 185  
 
D.9.3 IR                                             
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D.9.4 LRMS [M+Li], [M+Na], and [M+K]                                  
  
D.10 Methyl 6-isopropyl-8-oxo-8-(phenylamino)octanoate (13e) 
D.10.1 
1
H NMR  
 
 187  
 
D.10.2  
13
C NMR  
 
 188  
 
D.10.3 IR                                                
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D.10.4 HRMS                          
  
D.11 N
8
-Hydroxyl-3-methyl-N
1
-phenyloctanediamide (14a) 
D.11.1 
1
H NMR  
 
 190  
 
D.11.2 
13
C NMR  
 
 191  
 
D.11.3 IR                                           
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D.11.4 HRMS                                                              
    
D. 12 N
8
-Hydroxyl-N
8
, 3-diphenyloctanediamide (14b) 
D.12.1 
1
H NMR   
 
 193  
 
D.12.2 
13
C NMR 
 
 194  
 
D.12.3 IR                                                              
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D.12.4 HRMS                             
  
D.13 3-(tert-Butyl)-N
8
-hydroxyl-N
1
-phenyloctanediamide (14c) 
D.13.1 
1
H NMR 
 
 196  
 
D.13.2 
13
C NMR 
 
 197  
 
D.13.3 IR                                         
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D.13.4 HRMS                          
     
D.14 3-(2-Ethylhexyl)-N
8
-hydroxyl-N
1
-phenyloctanediamide (14d) 
D.14.1 
1
H NMR 
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D.14.2 
13
C NMR 
 
 200  
 
D.14.3 IR                                                            
 
 
D.14.4 HRMS                                                          
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APPENDIX E. DOSE RESPONSE GRAPHS AND DATA FOR C7-SAHA 
LIBRARY 
 
Table E.1. Percentage HDAC activity after incubation of SAHA with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 75 75 76 75 0 
6.25 x 10
-8
 63 56 51 57 3 
1.25 x 10
-7
 44 35 40 40 3 
2.5 x 10
-7
 31 21 26 26 3 
5.0 x 10
-7
 20 16 15 17 2 
 
 
Figure E.1. Dose response curve of SAHA tested using the HDAC activity from 
HeLa cells lysates from three independent trials. In some case, the error bar is 
smaller than the marker size. Data were fit to the sigmoidal curve using 
Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets were the 
results of the data analysis. The data are reported in Table 4.1.   
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Table E.2. Percentage HDAC activity after incubation of C7-SAHA pyridyl 
analogue 22d with Hela Lysate 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.11 x 10
-7
 70 70 86 75 5 
3.33 x 10
-7
 63 66 49 59 5 
1.00 x 10
-6
 45 24 31 33 6 
3.00 x 10
-6
 18 5 18 14 4 
9.00 x 10
-6
 8 -2 24 3 3 
 
 
 
Figure E.2. Dose response curve of  C7-SAHA pyridyl analogue 22d tested 
using the HDAC activity from HeLa cells lysates from three independent trials. 
Data were fit to the sigmoidal curve using Kaleidograph 4.0 (Synergy Software) 
to determine the IC50. The insets are the results of the data analysis. The data 
were reported in Table 4.2.   
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Table E.3. Percentage HDAC activity after incubation of C7-SAHA 
methylanthracene analogue 22f with Hela Lysate. 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E. 
4.10 x 10
-9
 81 76 75 77 2 
1.23 x 10
-8
 47 60 61 56 4 
3.70 x 10
-8
 33 38 49 40 4 
1.11 x 10
-7
 27 15 23 22 3 
3.33 x 10
-7
 10 12 13 12 1 
1.00 x 10
-6
 7 5 8 7 1 
 
 
 
Figure E.3. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f 
tested using the HDAC activity from HeLa cells lysates from three independent 
trials. In some case, the error bars are smaller than the marker size. The insets 
were the results of the data analysis. The data are reported in Table 4.2. 
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Table E.4. Percentage HDAC activity after incubation of C7-SAHA 
methyltetrahydro-anthracene analogue 22g with Hela Lysate. 
Concentration (M) Trial 1 Trial 2 Trial 3 Mean S.E. 
1.00 x 10
-8
 92 124 92 102 10 
5.00 x 10
-8
 38 68 76 60 11 
2.50 x 10
-7
 27 27 30 28 1 
1.25 x 10
-6
 11 25 15 17 4 
6.25 x 10
-6
 -2 2 0.5 0 1 
 
 
Figure E.4. Dose response curve of C7-SAHA tetrahydroanthracenylmethyl 
analogue 22g  tested using the HDAC activity from HeLa cells lysates from 
three independent trials with error bars indicating standard error. In some case, 
the error bars are smaller than the marker size. Data were fit to the sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
insets were the results of the data analysis. The data are reported in Table 4.2. 
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Table E.5.  Deacetylase activity percentage remaining after incubation of 
HDAC1, HDAC3, or HDAC6 with SAHA and the C7-SAHA analogues 22a-g.
 
Compound 
 
HDAC 
Isoform 
Trial 1 Trial 2 Mean S.E. 
 
SAHA 
(125 nM) 
 
HDAC1 30 35 32 2 
HDAC3 44 45 44 1 
HDAC6 32 36 34 2 
 
C7-Methyl 
(100 nM) 
HDAC1 38 52 45 7 
HDAC3 27 57 42 10 
HDAC6 21 35 28 7 
 
C7-Benzyl 
(100 nM) 
HDAC1 66 87 76 10 
HDAC3 54 88 71 11 
HDAC6 55 66 60 5 
 
C7-Pyridyl 
(500 nM) 
HDAC1 44 68 56 10 
HDAC3 101 92 97 4 
HDAC6 62 55 59 3 
 
C7-Tetrahydro-
anthracene 
(100 nM) 
HDAC1 64 66 65 1 
HDAC3 47 60 53 6 
HDAC6 76 84 80 4 
 
C7-Biphenyl 
(100 nM) 
 
HDAC1 91 114 102 10 
HDAC3 91 96 93 2 
HDAC6 71 82 76 5 
 
C7-Naphthyl 
(10 nM) 
HDAC1 103 121 112 9 
HDAC3 55 60 57 2 
HDAC6 82 104 93 10 
 
C7-Anthracene 
(500 nM) 
HDAC1 42 47 44 2 
HDAC3 89 90 89 0 
HDAC6 50 56 53 3 
 
Deacetylase activity of HDAC1, HDAC3 and HDAC6 was determined with SAHA 
and with C7-SAHA analogues at given concentration using an in vitro 
fluorescence assay as described (Section 3.6). The fluorescence activity of 
background (No enzyme added) was subtracted from the no small molecule 
treated (positive control) and the percentage of the deacetylase activity was set 
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to 100%.  Deacetylase activity percentage of each independent trial, mean 
percentage of deacetylase activity, and standard error (S.E.) are illustrated. The 
data are reported in the manuscript in Figure 4.2. 
Table E.6. HDAC1 activity percentage after incubation of SAHA. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 68 91 82 80 7 
6.25 x 10
-8
 55 62 57 58 2 
1.25 x 10
-7
 48 27 37 37 6 
2.50 x 10
-7
 37 40 25 34 5 
 
 
 
Figure E.5. Dose response curve of SAHA tested using the HDAC1 activity from 
three independent trials with error bars indicating standard error. In some case, 
the error bar is smaller than the marker size. Data were fit to the sigmoidal curve 
using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets 
were the results of the data analysis. The data are reported in Table 4.3.   
 
 
 
 
 207  
 
 
 
 
 
Table E.7. HDAC3 activity percentage after incubation of SAHA. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 88 78 74 80 4 
6.25 x 10
-8
 76 74 70 73 2 
1.25 x 10
-7
 63 45 44 56 5 
2.50 x 10
-7
 27 39 37 34 4 
 
 
Figure E.6. Dose response curve of SAHA tested using the HDAC3 activity from 
three independent trials with error bars indicating standard error. In some case, 
the error bar is smaller than the marker size. Data were fit to the sigmoidal curve 
using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The insets 
were the results of the data analysis. The data are reported in Table 4.3.   
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Table E.8. HDAC6 activity percentage after incubation of SAHA. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.125 x 10
-8
 66 76 73 72 3 
6.25 x 10
-8
 64 62 60 62 1 
1.25 x 10
-7
 37 28 32 32 2 
2.50 x 10
-7
 13 12 9 11 1 
 
 
Figure E.7. Dose response curve of SAHA tested using the HDAC6 activity from 
three independent trials with error bars indicating standard error. In some case, 
the error bars are smaller than the marker size. Data were fit to the sigmoidal 
curve using Kaleidograph 4.0 (Synergy Software) to determine the IC50. The 
insets were the results of the data analysis. The data are reported in Table 4.3.   
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Table E.9. HDAC1 activity percentage after incubation of C7-SAHA 
anthracenylmethyl 22f. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.11 x 10
-7
 103 96 86 96 4 
3.33 x 10
-7
 33 42 43 39 3 
1.00 x 10
-6
 17 16 17 17 0 
 
 
Figure E.8. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f 
tested using the HDAC1 activity from three independent trials with error bars 
indicating standard error. Data were fit to the sigmoidal curve using Kaleidograph 
4.0 (Synergy Software) to determine the IC50. The insets were the results of the 
data analysis. The data are reported in Table 4.3.   
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Table E.10. HDAC3 activity percentage after incubation of C7-SAHA 
anthracenylmethyl 22f. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
3.33 x 10
-7
 84 87 86 86 1 
1.00 x 10
-6
 51 57 70 59 5 
3.00 x 10
-6
 13 23 27 21 4 
 
 
Figure E.9. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f 
tested using the HDAC3 activity from three independent trials with error bars 
indicating standard error. In some case, the error bar is smaller than the marker 
size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 (Synergy 
Software) to determine the IC50. The insets are the results of the data analysis. 
The data were reported in Table 4.3.   
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Table E.11. HDAC6 activity percentage after incubation of C7-SAHA 
anthracenylmethyl 22f. 
Concentration 
(M) 
Trial 1 Trial  2 Trial 3 Mean Standard Error 
(S.E.) 
1.00 x 10
-7
 85 84 63 77 7 
3.00 x 10
-7
 52 53 56 54 1 
9.00 x 10
-7
 37 36 44 39 2 
 
 
Figure E.10. Dose response curve of C7-SAHA anthracenylmethyl analogue 22f 
tested using the HDAC6 activity from three independent trials with error bars 
indicating standard error. In some case, the error bar is smaller than the marker 
size. Data were fit to the sigmoidal curve using Kaleidograph 4.0 (Synergy 
Software) to determine the IC50. The insets were the results of the data analysis. 
The data were reported in Table 4.3.   
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APPENDIX F. SUPPLEMENTARY INFORMATION FOR C7-SAHA LIBRARY 
 
F.1. 1,1-Dibenzyl 6-methyl hexane-1, 1, 6-tricarboxylate (24). 
F.1.1.
 1
H NMR       
       
F.1.2.
 13
C NMR     
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F.1.3. IR                               
 
 214  
 
F.1.4. HRMS         
 
 
F.2. 6, 6-Dibenzyl 1-methyl 7-(pyridine-4-yl)heptane-1, 6, 6-tricarboxylate (25).  
F.2.1. 
1
H NMR                     
 
 215  
 
F.2.2.
 13
C NMR         
 
 216  
 
F.2.3. IR                  
 
 217  
 
F.2.4. HRMS                                       
 
 
F.3. Benzyl 6-bromohexanoate (16). 
F.3.1.
 1
H NMR                  
              
 218  
 
F.3.2.
 13
C NMR                    
 
 219  
 
F.3.3. IR                 
 
 220  
 
F.3.4. HRMS              
 
 
F.4. 6-Benzyl 1,1-di-tert-butyl hexane-1,1,6-tricarboxylate (17). 
F.4.1.
 1
H NMR            
 
 221  
 
F.4.2.
 13
C NMR                       
 
 222  
 
F.4.3. IR                          
 
 223  
 
F.4.4. LRMS            
                           
 
F.5. 1-Benzyl 6,6-di-tert-butyl 7-(pyridine-4-yl)heptane-1,6,6-tricaboxylate (18d).  
F.5.1.
 1
H NMR                   
 
 224  
 
F.5.2.
 13
C NMR                       
 
 225  
 
F.5.3. IR                                    
 
 226  
 
F.5.4. HRMS                   
 
 
F.6. Benzyl 8-oxo-8-(phenylamino)-7-(pyridine-4-ylmethyl)octanoate  (20d).  
F.6.1.
 1
H NMR                
 
 227  
 
F.6.2.
 13
C NMR               
             
F.6.3. IR                                  
 
 228  
 
F.6.4. HRMS                             
 
 
F.7. N
8
-hydroxy-N
1
-phenyl-2-(pyridin-4-ylmethyl)octanediamide (22d) 
F.7.1.
 1
H NMR                              
 
 229  
 
F.7.2. 
13
C NMR                   
 
 230  
 
F.7.3. IR                                     
 
 231  
 
F.7.4. HRMS                                    
 
F.7.4. HPLC                                     
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ABSTRACT 
 
THE STRUCTURAL REQUIREMENTS OF HISTONE DEACETYLASE 
INHIBITORS: SUBEROYLANILIDE HYDROXAMIC ACID (SAHA) ANALOGUES 
MODIFIED AT C3, C6, AND C7 POSITIONS ENHANCE SELECTIVITY 
 
by 
SUN EA CHOI 
May 2012 
Advisor: Dr. Mary Kay H. Pflum 
Major: Chemistry (Organic) 
Degree: Doctor of Philosophy 
Histone deacetylase (HDAC) proteins are targets for drug design towards 
the treatment of cancers since overexpression of HDAC proteins is linked to 
cancer. Several HDAC inhibitors, including the FDA approved drug suberoyl-
anilide hydroxamic acid (SAHA, Vorinostat), have cleared clinical trials and 
emerged as anti-cancer drugs. However, SAHA inhibits all of the 11 metal ion-
dependent HDAC proteins. Therefore, we synthesized several libraries of small 
molecule HDAC inhibitors based on SAHA to help understand the structural 
requirements of inhibitory potency and isoform selectivity. 
In previous work, 
SAHA analogues 
functionalized at the C2 
position (C2-SAHA 
analogues) near the 
metal binding hydroxamic 
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acid displayed decreased inhibitory activity compared to the parent compound, 
SAHA. The lack of potency of the C2 library indicated that limited flexibility exists 
in the HDAC active site near the hydroxamic acid. Therefore, we theorized the 
substituents on the C3, C4, C5, C6, and C7 positions would display more potent 
inhibition compared to the C2-SAHA library due to the more solvent exposed 
location. Interestingly, while the C2-SAHA analogues containing any substituents 
were poor potent, the C3-SAHA analogue with a methyl substituent displayed 
potency. The potency of the remaining analogues decreased with increasing size 
of the C3 substituents. Moreover, the C6-SAHA phenyl analogue even displayed 
potency in the submicromolar range. Finally, most of the C7-SAHA analogues 
displayed equal or greater potency compared to SAHA. The results indicate that 
more flexibility in the HDAC active site exists closer to the capping group region 
near the C6 and C7 positions, while only modest flexibility exists in the bottom of 
the active site near the C2 and C3 positions. 
After analyzing the potency of SAHA analogues, isoform selective 
inhibition of the individual compounds was evaluated. Seven of the SAHA 
analogues demonstrated 
selectivity.  The C3-SAHA 
ethyl-substituted analogue 
showed preference for 
HDAC6 over HDAC1 and 
HDAC3 even though it 
displayed decreased potency. 
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The C6-SAHA analogues displayed diverse selectivity; the C6-SAHA methyl 
variant displayed preference for class I, t-butyl variant showed a dual-HDAC1 
and HDAC6 selectivity, and 2-ethylhexyl variant showed HDAC3-selectivity. The 
C7-SAHA analogues displayed selective inhibition as well; the C7-SAHA 
pyridylmethyl and anthracenylmethyl variants displayed a dual-HDAC1 and 
HDAC6 selectivity, and naphthylmethyl variant showed HDAC3-selectivity. The 
interesting potency and selectivity of linker-modified SAHA analogues suggest 
that linker region substituents can be exploited in the design of new anti-cancer 
drugs.  
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